Next Article in Journal
The Role of Proteomics in Bacterial Response to Antibiotics
Next Article in Special Issue
Histological Effects of Intravitreal Injection of Antifungal Agents in New Zealand White Rabbits: An Electron Microscopic and Immunohistochemical Study
Previous Article in Journal
Curcumin Diglutaric Acid, a Prodrug of Curcumin Reduces Pain Hypersensitivity in Chronic Constriction Injury of Sciatic Nerve Induced-Neuropathy in Mice
Previous Article in Special Issue
Ocular Co-Delivery of Timolol and Brimonidine from a Self-Assembling Peptide Hydrogel for the Treatment of Glaucoma: In Vitro and Ex Vivo Evaluation
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Pharmaceuticals
Volume 13
Issue 9
10.3390/ph13090213
pharmaceuticals-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Proteomics Reveals the Potential Protective Mechanism of Hydrogen Sulfide on Retinal Ganglion Cells in an Ischemia/Reperfusion Injury Animal Model

by
Hanhan Liu
1,
Natarajan Perumal
1,
Caroline Manicam
1,
Karl Mercieca
2 and
Verena Prokosch
3,*
1
Experimental and Translational Ophthalmology, University Medical Centre of the Johannes Gutenberg University Mainz, 55131 Mainz, Germany
2
Royal Eye Hospital, School of Medicine, University of Manchester, Manchester M13 9WH, UK
3
Department of Ophthalmology, University Medical Centre of the Johannes Gutenberg University Mainz, 55131 Mainz, Germany
*
Author to whom correspondence should be addressed.
Pharmaceuticals 2020, 13(9), 213; https://0-doi-org.brum.beds.ac.uk/10.3390/ph13090213
Submission received: 28 July 2020 / Revised: 24 August 2020 / Accepted: 25 August 2020 / Published: 27 August 2020
(This article belongs to the Special Issue Advances in Ocular Pharmacology)
Browse Figures
Review Reports Versions Notes

Abstract

:
Glaucoma is the leading cause of irreversible blindness and is characterized by progressive retinal ganglion cell (RGC) degeneration. Hydrogen sulfide (H2S) is a potent neurotransmitter and has been proven to protect RGCs against glaucomatous injury in vitro and in vivo. This study is to provide an overall insight of H2S’s role in glaucoma pathophysiology. Ischemia-reperfusion injury (I/R) was induced in Sprague-Dawley rats (n = 12) by elevating intraocular pressure to 55 mmHg for 60 min. Six of the animals received intravitreal injection of H2S precursor prior to the procedure and the retina was harvested 24 h later. Contralateral eyes were assigned as control. RGCs were quantified and compared within the groups. Retinal proteins were analyzed via label-free mass spectrometry based quantitative proteomics approach. The pathways of the differentially expressed proteins were identified by ingenuity pathway analysis (IPA). H2S significantly improved RGC survival against I/R in vivo (p < 0.001). In total 1115 proteins were identified, 18 key proteins were significantly differentially expressed due to I/R and restored by H2S. Another 11 proteins were differentially expressed following H2S. IPA revealed a significant H2S-mediated activation of pathways related to mitochondrial function, iron homeostasis and vasodilation. This study provides first evidence of the complex role that H2S plays in protecting RGC against I/R.

1. Introduction

Glaucoma is one of the leading causes of irreversible blindness worldwide [1] and is characterized by progressive optic nerve and retinal ganglion cell (RGC) degeneration [2]. Although elevated intraocular pressure (IOP) is the main risk factor and mainstay of treatment, simply lowering IOP may fail to halt the disease progression in many patients despite delaying RGC death. Novel strategies which halt RGC loss are desperately needed to prolong visual function in glaucoma [3].
Along with carbon monoxide (CO) and nitric oxide (NO), hydrogen sulfide (H2S), has been recognized as a third endogenous gaseous signaling molecule [4]. The importance of NO in biology and medicine was highlighted in 1998 when the Nobel Prize was awarded in Physiology and Medicine to Robert Furchgott, Louis Ignarro and Ferid Murad for their pioneering work on the role of NO in the nervous, cardiovascular and immune systems [5]. In the same time period, CO has also been recognized as putative neurotransmitters [6]. They are both involved in several important aspects of neuronal function. In physiological condition, NO formed in the eye is beneficial in preventing the genesis of glaucoma or halting its progress; however, excessive NO would become pathogenic in the progress of glaucomatous optic neuropathy [7]. In vitro and in vivo studies have shown evidence of NO’s involvement in retinal degeneration, the regulation of IOP and the production of aqueous humor [8,9,10]. Drugs inhibiting NO formation showed protective effects in the retina against elevated IOP in glaucoma animal models [11,12,13]. On the other hand, The CO production system in the retina has been highlighted as a protective mechanism, its protecting role is demonstrated in the regulation of Ischemia-reperfusion (I/R) -induced damage, protecting retinal ganglion cells against oxidative damage, increases retinal and choroidal blood flows and downregulating inflammatory response in the anterior segment of the eye [14,15,16]. Only recently, has H2S been recognized as a physiological gasotransmitter of comparable importance to NO and CO [17]. It is produced via cysteine catabolism by the cytoplasmic enzymes, cystathionine-β-synthase (CBS) and cystathionine-γ-lyase (CSE), and also via 3-mercaptopyruvate catabolism by 3-mercaptopyruvate sulfurtransferase (3-MST) [18]. H2S has recently been considered an endogenous gasotransmitter with protective potential at low concentrations. Alteration of endogenous H2S levels in the retina is also linked to different pathological conditions, and its exogenous donors have been shown to exhibit potential in protecting retinal ganglion cells against insults such as diabetic retinopathy, ischemia-reperfusion injury and N-methyl-D-aspartic acid (NMDA)-induced excitatory neurotoxicity [16,19,20]. We showed in our previous study that endogenous H2S synthesis via 3-MST is increased in a glaucoma animal model after seven weeks of IOP elevation. Furthermore, we documented that GYY4137, a slow-release H2S donor, effectively protected RGC against different glaucomatous injuries in vitro and in vivo, in a dose-dependent manner [21].
The neuroprotective effect of H2S was partly attributed to its capability of vasorelaxation, anti-oxidative stress, neuroendocrine regulation and inflammation suppression [22,23,24], but our current understanding of the mechanism behind RGC apoptosis and protective properties of H2S is far from comprehensive.
In this study we examined the potential protective mechanisms activated by H2S in a glaucoma animal model. In this work, we used mass spectrometry-based proteomics to elucidate how protein expression changes at the cellular level, in H2S-treated and H2S-untreated retinae of Sprague-Dawley rats that underwent acute elevated IOP (ischemia-reperfusion injury), and to provide a more precise direction for further studies.

2. Results

2.1. Pretreatment of H2S Improves RGC Survival against Ischemia-Reperfusion Injury

IOP of the animals was elevated to 55 mmHg for 60 min to induce regional ischemic injury, followed by 24 h of reperfusion. I/R injury resulted in significant reduction in the number of RGC in the operated eyes (1101.7 ± 116.4 RGC/mm2) compared to the contralateral control (1310.6 ± 236.4 RGC/mm2). While injection of the H2S precursor, GYY4137, prior to I/R injury significantly improved RGC survival (1295.4 ± 136.1 RGC/mm2). Total number of RGC between control and H2S treated group is not significantly different (Figure 1) (*** p < 0.001, ** p < 0.01, n = 6 per group, means ± SD).

2.2. Proteomic Profiling

MS-based discovery proteomics was used to identify and distinguish proteome profiles of rat retina undergoing I/R injury with or without pre-treatment of H2S. In total 1115 retinal proteins were identified with a false discovery rate (FDR) of 1% (the complete list of proteins can be found as Supplementary Data S1 “Total proteins”). Ischemia/reperfusion injury with (1046 proteins) or without H2S pretreatment (1015 proteins) resulted in the expression of a slightly lower number of proteins than the control group (CTRL; 1070 proteins). All three groups showed an overlap of 963 proteins (Figure 2B). Furthermore, 34 proteins were exclusively expressed in the control, 14 proteins in I/R group and H2S group.

2.3. Differential Expression of Retinal Proteins between I/R and H2S Groups

A total number of 79 proteins were found to be significantly differentially expressed (p < 0.05) in the retinal samples of both I/R and H2S groups compared to the control group. A slightly higher correlation was observed between the H2S vs. CTRL group compared with I/R vs. CTRL group, which indicates high similarities between the proteome of control and H2S pre-treated groups. A heat map with unsupervised hierarchical clustering of retina proteome in I/R, H2S and CTRL groups shows the segregation of identified proteins into various clusters (Figure 2C, also can be found in Supplementary Data S2).
Forty-eight proteins were found to be differentially expressed (p < 0.05) in the retina samples of the I/R group compared to the CTRL group (listed in Table 1, also see Figure 3A). The five most significantly down-regulated proteins are 116 kDa U5 small nuclear ribonucleoprotein component (EFTUD2), E3 ubiquitin-protein ligase NEDD4 (Nedd4), adenylyl cyclase-associated protein 1 (CAP1), mucin-19 (MUC19) and hydroxymethylglutaryl-CoA lyase, mitochondrial (Hmgcl). The five most significantly up-regulated proteins are vesicular inhibitory amino acid transporter(SLC32A1), inorganic pyrophosphatase (PPA1), AP-2 complex subunit mu (AP2M1), mannose-P-dolichol utilization defect 1 protein (MPDU1) and NADH-cytochrome b5 reductase 3(Cyb5r3).
Closer examination of the protein levels within each of the dominant clusters showed two major clusters of proteins that were involved in the mechanism underlying the neuroprotective properties of H2S against I/R.
First, among 48 proteins, which were differentially expressed in the retina samples of I/R group compared to CTRL group, a cluster of 18 proteins can be restored to near normal or normal level by H2S pretreatment, which comprised 22.78% of the total differentially expressed proteins due to I/R injury (Table 2, Figure 3B,C). Proteins were classified by PANTHER classification system into six categories, which are cytoskeletal protein, membrane traffic protein, metabolite interconversion enzyme, nucleic acid binding protein, protein modifying enzyme and translational protein.
The five proteins, which are most significantly up-regulated by H2S pretreatment compared to I/R group, are CaM kinase-like vesicle-associated protein (CAMKV), trifunctional enzyme subunit alpha (Hadha), solute carrier family 2, facilitated glucose transporter member 1(Slc2a1), Hmgcl and SURP and G-patch domain-containing protein 2 (SUGP2). Furthermore, the proteins that were significantly down-regulated by H2S, included mannose-P-dolichol utilization defect 1 protein (MPDU1), tripeptidyl-peptidase 2 (Tpp2), NADH-cytochrome b5 reductase 3(Cyb5r3), eukaryotic translation initiation factor 3 subunit E (Eif3e) and 26S proteasome non-ATPase regulatory subunit 13 (PSMD13).
The second cluster was characterized by the expression of certain proteins, which were only differentially expressed due to pre-treatment of H2S (Table 3, Figure 3D–E). Proteins were classified by PANTHER classification system into five categories, calcium-binding protein, cytoskeletal protein, metabolite interconversion enzyme, nucleic acid binding protein and translational protein. Pre-treatment of H2S significantly increased the abundance of glutaredoxin-3(Glrx3), dynein light chain roadblock-type 1(Dynlrb1) and probable ATP-dependent RNA helicase DDX5(DDX5), and significantly decreased the abundance of small nuclear ribonucleoprotein G(SNRPG), annexin A6(Anxa6) and keratin, type II cytoskeletal 1(KRT1).

2.4. Pathway Analysis of the Differentially Expressed Retinal Proteins in I/R and H2S Groups

To better understand the roles of H2S in I/R injury, we utilized the Ingenuity Pathway Analysis (IPA) software to identify the protein-protein interaction (PPI) networks and canonical pathways of the differentially expressed proteins. The most significantly affected pathways due to I/R comprised ketogenesis are, formaldehyde oxidation II, phototransduction pathway, anandamide degradation and heme degradation (Table 4). Amongst which, pathways such as ketogenesis, gamma-aminobutyric acid (GABA) receptor signaling, leucine degradation I and ketolysis, are significantly restored following H2S pre-treatment.
Compared to the CTRL group, administration of H2S also significantly modulated pathways, such as NER pathway, oxidative phosphorylation and estrogen receptor signaling (Table 5).
To further explore the protein–protein interaction (PPI) networks of the clusters of differentially expressed proteins, functional pathway enrichment was analyzed in the I/R group, H2S-restored proteins and H2S-modulated proteins. The global view of the interactions between proteins that were differentially regulated in the I/R group is shown in Figure 4. The proteins with the most interactions were EFTUD2, AP2M1, Hadha, Heat shock 70 kDa protein 1-like (HSPA1L) and Plastin-3 (PLS3). EFTUD2 was found to obtain the highest number of PPI (13 PPIs), followed by AP2M1 with 4 PPIs.
Among the 18 proteins restored by H2S pretreatment, there is a low determined PPI. EFTUD2 and AP2M1 shown less PPIs, 8 and 3 PPIs, respectively (Figure 5A).
A number of 11 proteins were modulated by H2S compared to CTRL group, among which, COP9 signalosome complex subunit 6 (COPS6) and DDX5 have the highest number of PPIs (Figure 5B).

3. Discussion

Ever since H2S has been recognized as the third endogenous gaseous signaling molecule alongside CO and NO, its role in various physiological and pathological processes has been explored. In our previous study, endogenous H2S synthases are observed to increase in a glaucoma animal model after seven weeks of chronic elevated IOP. Furthermore, we demonstrated that administration of GYY4137, a slow-release H2S donor, significantly improved RGC survival under different glaucomatous injuries in vitro and in vivo [21]. The neuroprotective effect of H2S in the retina was partly attributed to its capability of vasorelaxation, anti-oxidative stress, neuroendocrine regulation and inflammation suppression [25] but the underlying mechanism and the specific protein interaction networks and the mechanisms involved in protective properties of H2S remain to be elucidated. Building on previous results, we employed a mass spectrometry-based proteomics approach to analyze the retinal proteome, and bio-informatics to algorithmically generate protein connections, which allowed us to identify the most plausible signaling pathway alterations related to H2S’s neuroprotective properties against ischemia-reperfusion injury in present study. This is to our knowledge, the first study to address the intricate alterations at the protein level, which can be attributed to the treatment with exogenous H2S, and to show how these molecules play a pivotal role in restoring retinal homeostasis against I/R injury in vivo.
Following I/R injury, the abundance of 48 proteins was significantly altered. Changes of the signaling pathways involved in mitochondrial homeostasis and function, calcium dysregulation, cytotoxicity regulation, reactive oxygen species (ROS) scavenging, neural transduction and vascular function were found. The proteins, which were regulated by H2S were categorized into two clusters: (1) a cluster 18 proteins, the abundance of which was significantly altered in I/R, and was then restored to normal or near normal level by H2S; (2) a cluster of 11 proteins, the abundance of which was significantly altered due to H2S administration compared to the CTRL group. Based on the results from the ingenuity pathway analysis, the signaling pathways regulated by H2S comprised iron homeostasis and ROS regulation, mitochondrial homeostasis and function, vasodilation and DNA repairing.

3.1. Changes in Iron Homeostasis and ROS Regulation

Redox mechanisms are known to partially contribute to the protective properties of H2S in various tissues. Firstly, we observed that the Slc2a1 level is significantly downregulated in I/R and restored by H2S. Slc2a1 facilitates docosahexaenoic acid (DHA), the oxidized form of vitamin C, transport across the inner blood-retina barrier and converts DHA to ascorbic acid and accumulates as ascorbic acid in the retina [26]. As the Slc2a1 level is downregulated following I/R injury, vitamin-C transport is downregulated accordingly. Vitamin C is the primary circulatory antioxidant to be quickly used and depleted when excessive ROS is generated by the pathophysiological pathways triggered by I/R injury, therefore sparing other endogenous antioxidants [27]. Oxidative stress promotes the oxidation of ascorbic acid to DHA, which is shown by studies to promote neuronal death under oxidative stress [28]. Downregulated vitamin-C transport indicates that I/R injury impaired the anti-oxidative property of the retina. H2S increased vitamin-C transport, subsequently strengthening the anti-oxidative property of the retina as opposed to the ROS generated due to I/R.
Secondly, several proteins involved in iron homeostasis, such as biliverdin reductase A (Blvra), Cyb5r3 and Glrx3, were differentially abundant due to I/R, H2S administration or both. Iron metabolism and regulation is crucial in mammals and is essential for physiological neuronal functions such as neural respiration and metabolic activities, myelin synthesis, neurotransmitter production and synaptic plasticity [29]. However, its overload triggers axonal degeneration and neuronal cell death [30]. Excessive iron may catalyze the formation of highly reactive hydroxyl radicals, which eventually induce the accumulation of ROS [31,32]. Nevertheless, it is well known that the disproportionally increased brain Fe level is correlated with neurodegenerative diseases such as Parkinson’s disease, Alzheimer’s disease, Huntington’s disease and neurodegeneration with brain Fe accumulation.
Most of the body’s Fe is contained within the protoporphyrin ring of heme [32]. Heme is essential for the survival of organisms, while being potentially toxic. The excessive release of heme from hemoproteins can lead to the generation of unfettered oxidative stress and programmed cell death [29]. Heme degradation is therefore important for maintaining iron homeostasis and preventing its cytotoxicity and oxidative stress [33].
The abundance of Blvra, the main isoform of biliverdin reductase [34], is significantly increased due to I/R injury. Increased Blvra level corresponds to upregulated heme degradation.
Blvra is a pleiotropic enzyme primarily known for reducing heme-derived biliverdin into the powerful antioxidant and anti-nitrosative molecule bilirubin [35,36]. Bilirubin is able to inhibit free radical chain reactions and protects against oxidant-induced damage [37]. Studies reported that reducing Blvra level in cells or knockout Blvra gene in mice both led to increased oxidative stress [37,38]. On the other hand, increasing the levels of Blvra is beneficial through an increase in intracellular bilirubin generation and direct signaling through cytoprotective pathways [34,39,40].
Cyb5r3, the principal reductase in mitochondria, is also significantly upregulated due to I/R injury, and can be restored by H2S. Cyb5r3 is also a heme reductase and recycles oxidized heme (Fe3+) back to its reduced form (Fe2+) [41]. Upregulation of Blvra and Cyb5r3 levels following I/R injury is likely to confer self-protection against oxidative stress.
Glrx3 level was the most significantly modulated by H2S when compared to the control group, while it was not impacted by I/R injury. Depletion of Glrx3 in mammalian cells was associated with moderate deficiencies of cytosolic Fe-S cluster enzymes and evidence of altered iron homeostasis [42]. Overexpressed Glrx3 can compensate for the lack of other reducing equivalents [43].
Glrx3 belongs to the glutaredoxin family, it utilizes the reducing power of glutathione to maintain and regulate the cellular redox state and is essential for iron-sulfur (Fe-S) cluster assembly [44,45]. Iron-sulfur clusters are ancient, ubiquitous cofactors composed of iron and inorganic sulfur which participate in numerous biological processes [46,47,48,49].
In mammalian cells, Glrx3 localizes to the cytosol and it has been proposed that it plays dual roles in iron trafficking and regulation [50,51]. Glrx3 is a monothiol glutaredoxin, being able to form (2Fe-2S) cluster-bridged dimers and deliver Fe-S clusters to recipient proteins [52,53].
Detoxification of neural Fe overload is a potential therapeutic approach in the treatment of neurodegenerative disease. Based on the results of proteomic and IPA analysis, we assume that, when exposed to oxidative stress, cells increase their capability to reduce oxidized heme and to degrade it, which partially contributes to a self-protective mechanism that reduces the deleterious effects of free heme. H2S plays a similar reducing role as Cyb5r3 in recycling oxidized heme to its reduced state; the abundance of Cyb5r3 was thus not increased when H2S was present. Nevertheless, H2S has shown a strong association with Glrx3, which is able to regulate cellular iron homeostasis [54,55].

3.2. Changes in Retinal Metabolism, Mitochondrial Homeostasis and Function

As mentioned above, the abundance of Slc2a1 is significantly downregulated in I/R and restored by H2S to near normal levels, which also corresponds to increased HIF1α signaling. Slc2a1 abundance in HIF1α signaling plays a key role in promoting neuronal survival by mediating the endogenous protective responses after hypoxia-ischemia. In glaucoma mice, decreased HIF1α expression is observed to be correlated with RGC loss [56]. H2S regulates HIF1 factors in different patterns, depending on different cell types and experimental conditions. It increases expression of the HIF1α in rat brain capillary endothelial cells and in mouse spinal-cord primary culture [57,58], and inhibits HIF1 activation in human hepatoma Hep3B cells, cervical carcinoma HeLa cells and aortic smooth-muscle cells [59,60].
Our proteomic data indicate that H2S administration increased HIF1α signaling. Upregulating expression of HIF1α induces an increase of aerobic glycolysis, which transforms glucose to lactate and generates nicotinamide adenine dinucleotide (NAD+) [61]. HIF1 also directly induces pyruvate dehydrogenase kinase 1 [62], which phosphorylates the pyruvate dehydrogenase (PDH) complex, and consequently inhibits PDH complex from catalyzing pyruvate to form acetyl CoA. This fuels the mitochondrial tricarboxylic acid cycle (TCA) cycle, which provides the mitochondrial NADH needed to power electron transport. Hence, HIF1α actively represses mitochondrial respiration.
Furthermore, in this study, H2S reduced the abundance of NADH dehydrogenase (ubiquinone) 1 alpha subcomplex subunit 5 (Ndufa5), which subsequently also decreased mitochondrial respiration. Ndufa5, localizes to the inner mitochondrial membrane and is an accessory sub-unit of complex I [63]. Reducing Ndufa5 suppresses complex I activity [64,65]. It is generally believed, that mitochondrial complex I deficiency contributes to the process of neurodegeneration because of reduced adenosine triphosphate (ATP) production, oxygen consumption and increased ROS production. However, complex I has been reported as a site of mitochondrial ROS generation [66,67], and actively suppressing its activity may actually be protective. Neuronal complex I deficiency is not correlated with the neurodegeneration, mitochondrial DNA damage in Parkinson’s disease brain, nor in mice with a central nervous system knockout of Ndufa5 [64,68]. It has been shown in neurodegenerative disorders that reversible inhibition of complex I can be protective against ischemia-reperfusion injury by modifying mitochondrial ROS production [69,70].
Studies strongly suggest that active suppression of the TCA cycle, mitochondrial respiration and ROS production, as well as augmentation of ATP levels, are crucial for the cell survival under I/R injury [62,71]. We assume that by suppressing mitochondrial respiration through upregulating HIF1-α and downregulating Ndufa5 levels, H2S reduces mitochondrial oxidative phosphorylation, thereby repressing mitochondrial oxygen consumption and resulting in the relative increase of intracellular oxygen tension and limited ROS production under I/R.
As discussed above, mitochondrial PDH activity is attenuated by HIF1α following H2S administration. Neurons usually prefer glucose for energy, but when mitochondrial metabolism of pyruvate is limited, ketone bodies can be oxidized and release the only alternative source of acetyl CoA for neurons [72]. Using ketone bodies as an alternative energy source has shown neuroprotective effects in Alzheimer’s disease, Parkinson’s disease and ischemic and traumatic brain injury [73,74,75,76,77,78]. The metabolic pathway that produces ketone bodies is ketogenesis. In this study, the signaling pathways most significantly downregulated by I/R injury and then restored by H2S were ketogenesis, ketolysis and leucine degradation.
In comparison to glucose, ketone bodies have a higher inherent energy [79]. As ketone bodies provide more energy per unit of oxygen than glucose [80,81], in states of metabolic stress such as I/R injury, ketone bodies are more energy-efficient fuel for neurons. They can also bypass the inhibited PDH complex and maintain the metabolites of TCA cycle, therefore permitted continued ATP production under ischemia.
Administration of H2S has shown evidence of actively suppressing oxidative phosphorylation and limiting the utilization of glucose as the energy source, therefore increasing intracellular oxygen tension under ischemia and limiting ROS production during reperfusion. Furthermore, H2S promotes the utilization of ketone bodies as an alternative energy source, which is more energy-efficient than glucose and maintains ATP production. H2S therefore enhanced the ability of retinal neurons to withstand metabolic stress induced by I/R, which would normally deplete the resilience of the neurons and result in neuronal cell loss (see in Figure 6).

3.3. Changes in Retinal Vascular Function

Decreased average blood flow in the retina, optic nerve head and choroidal circulations is also demonstrated in glaucoma patients [82,83,84]. The “vascular theory” of glaucoma hypothesizes RGC loss as a consequence of insufficient blood supply [85]. Vasospasm and autoregulatory dysfunction have been postulated to reduce ocular blood flow [86]. Increased IOP has also been shown to reduce vascular caliber in rat retina while H2S acted as a vasodilator in our previous studies [21]. H2S can be endogenously generated in vascular smooth muscle cells. Its vasorelaxant potency is partially mediated by a functional endothelium [87].
However, I/R is known to cause endothelial dysfunction. In this study, eNOS signaling is downregulated following I/R injury. Endothelium-derived NO is a critical regulator of vascular homeostasis and tone [88]. NO continually regulates the diameter of blood vessels and maintains an anti-apoptotic environment in the vessel wall [89].
Downregulation of eNOS signaling is an indicator of impaired endothelial function, which results in diminished microcirculation and reduced response to endothelial-dependent vasodilators and vasoconstrictors. This causes dysregulated blood flow and loss of the endothelial barrier.
While eNOS signaling is downregulated, protein kinase A (PKA) signaling is significantly upregulated following I/R. PKA represents a signaling hub for a large variety of hormones, neurotransmitters and cytokines [90]. PKA has been shown to regulate different aspects of endothelial cell physiology [91,92,93], and to inhibit angiogenesis when activated [94,95]. Upregulation of PKA is likely a self-protective mechanism.
Furthermore, one of the most significantly upregulated proteins I/R, which can be restored by H2S to normal levels, is Cyb5r3. It is the principal reductase involved in the mitochondrial amidoxime reducing component (mARC)-containing enzyme system [96]. In vascular smooth muscle, Cyb5r3 functions as a soluble guanylyl cyclase (sGC) heme iron reductase, and is critical for vasodilation [97]. Through its reductase activity, Cyb5r3 maintains NO-sGC-cGMP function [98]. The NO-sGC-cGMP pathway in aortic smooth muscle cell (SMC) is known to relax SMC and dilate vessels [98].
Hydrogen sulfide and the −SH anion reduce a variety of organic substrates [99]. It is reasonable to assume that H2S plays a similar reducing role as Cyb5r3 in maintaining vascular relaxation and enabling a less constricted vascular environment due to I/R.
Although the abundance of DDX5 was not influenced by I/R injury, it is significantly more abundant following the administration of H2S. As DDX5 regulates the expression of a number of key regulators upstream of the estrogen-receptor [100], estrogen-receptor signaling was also significantly upregulated in our PPI results.
Increasing evidence suggests that estrogen exposure may have a neuroprotective effect on the progression of glaucoma and may alter its pathogenesis [101]. The vasodilation caused by estrogen and its effects on aqueous humor outflow may contribute [102]. These estrogen receptors are abundantly expressed throughout the eye, and in particular the retina and more specifically in the RGC [103,104]. In various CNS injuries and diseases, the activation of estrogen receptor signaling has shown neuroprotective effects via attenuation of neuro-inflammation and neurodegeneration [105]. In different animal models of RGC degeneration, activation of estrogen receptor attenuated RGC apoptosis under acute elevated IOP [106]; impaired estrogen receptor expression is observed in a mouse model with early RGC apoptosis [107]; and in Leber’s hereditary optic neuropathy cells activating estrogen receptors improve cell viability by reducing apoptosis [108]. Moreover, inhibition of estrogen synthesis is associated with IOP elevation and reduced RGC counts in female mice [109] and blockage of estrogen receptor signaling in rats intensifies impairment in visual function and retinal structure after ocular hypertension [110]. Although estrogen receptor signaling was not impacted by I/R injury in our study, activating estrogen receptor signaling via upregulating DDX5 is still one of the possible pathways through which H2S exerts protective effects and partially contributes to its capability of vasorelaxation, anti-oxidative stress and inflammation suppression.
H2S also significantly downregulated annexin A6 compared to the control group, which is a calcium dependent phospholipid binding protein [111].
Annexins are important in Ca(2+)-induced neurotoxicity or neuroprotection [112]. Annexin A6 has been shown to play a central role in vascular remodeling processes [113]. It has been demonstrated that annexin A6 accumulates and converts exosomes in vascular smooth muscle cells into calcifications under calcium stress, which is known to be induced by I/R [113]. Vascular smooth muscle cells contribute significantly to physiological regulation of vascular tone and arterial blood pressure [114]. The presence of coronary artery calcification is significantly associated with raised IOP regardless of conventional cardiovascular risk factors [115]. By reducing the abundance of annexin A6, H2S potentially makes the calcification in vascular smooth muscle cells subside due to I/R, thus maintaining vascular autoregulation.
PKA signaling and Cyb5r3 level is upregulated, likely serving as a self-protective mechanism to maintain endothelial function and vasodilation against I/R injury, while eNOS signaling is downregulated as an indication of endothelial dysfunction. Administration of H2S regulated the abundance of Cyb5r3 and activated estrogen receptor signaling to facilitate vascular relaxation. H2S also reduced the abundance of annexin A6, which plays a central role in artery calcification. Combined together, H2S enabled a less constricted vascular environment in the retina, thereby resulting in better retinal perfusion to counteract I/R injury (see Figure 7).

3.4. Changes in GABA Receptor Signaling

GABA receptor signaling is the most impacted signaling pathway by I/R and this can be restored by H2S. The AP2M1 and SLC32A1 levels are upregulated due to I/R, which correspond to upregulated GABA receptor signaling. gamma-aminobutyric acid (GABA) is the main inhibitory neurotransmitter in the mammalian brain [116]. In the retina, GABA is similarly important in neural inhibition with approximately 40% of all retinal cells having been described as GABAergic [117]. GABA-containing vesicles release the neurotransmitter into the synaptic cleft to bind with GABA receptors present on the post-synaptic neuron [118].
SLC32A1, solute carrier family 32 (GABA vesicular transporter) member 1, is a transmembrane transporter which is responsible for the storage of GABA or glycine in synaptic vesicles [119]. AP2M1 is highly expressed in the central nervous system [120,121], and encodes the μ-subunit of the adaptor protein complex 2 (AP-2) [122]. AP-2 regulates the neuronal surface levels of GABA and glutamate receptors [123,124]. An imbalance between excitatory and inhibitory synaptic transmission is thought to contribute to excitotoxicity and neuronal cell death during ischemic insult. AP-2 was found to be crucial in reducing the loss of synaptic GABA receptors during simulated ischemia in the rat brain [125]. Increased abundance of SLC32A1 and AP2M1 suggests raised retinal GABA levels following I/R injury, which may occur in order to maintain excitatory/inhibitory balance, thereby improving the survival of RGCs, the latter being most susceptible to extracellular glutamate.
However, similar to glutamate, the functions of GABA are also controversial. There is evidence that the retina is extremely sensitive to abnormally accumulated GABA and its resulting toxicity, particularly in the presence of ischemia [126,127,128]. An antiepileptic drug, vigabatrin (gamma-vinyl GABA), exerts its effect by increasing GABA levels [129]; as the drug increases retinal GABA levels much more significantly than in the brain and retina has a lower tolerance to GABA toxicity than the brain [127,128], one third of patients receiving vigabatrin present binasal visual field loss [130].
GABA also has a role in the regulation of vascular tone [127]. GABA receptors are known to interact with perivascular astrocytes which synthesize vasoactive materials [131,132]. In the rat retina, GABA is shown to be capable of eliciting both vasodilator and vasoconstrictor responses but endogenous GABA is unlikely to be an important regulator of resting vascular diameter and blood flow in the retina [133].
The exact role of GABA receptor signaling in this study is unclear but the results certainly raise intriguing questions about the involvement of GABA receptor signaling in neurodegeneration and the interaction between GABA signaling and H2S.

3.5. Changes in DNA Repair

The nucleotide excision repair (NER) pathway is at the top of the canonical pathways modulated by H2S, with a particularly significant upregulation of COPS6 level. In combination with the ubiquitin (Ub) proteasome system (UPS) the COP9 signalosome controls the stability of cellular regulators [134] and regulates several important intracellular pathways, including DNA repair, cell cycle, developmental changes, and some aspects of immune responses [135,136,137].
COPS6 has been shown to be cleaved by caspase 3 during apoptosis in vitro and in vivo [138] and this cleavage can be completely blocked by specific caspase 8 inhibitor [139]. Upregulation of COPS6 led to upregulation of the NER pathway, one of the major cellular DNA repair pathways for the removal of bulky helix lesions [140,141]. Enhancement of the NER pathway has shown protective effects in peripheral neurons both in vitro and in vivo [142]. The roles of DNA repair in neuronal cell survival and the response to aging and ROS such as that generated by mitochondrial respiration in glaucoma is of particular interest. The promotion of DNA repair by activation of the NER pathway through COP9 signalosome subunit upregulation could be an interesting aspect to explore in future studies.
Neurodegenerative diseases are characterized by decades of apparent normality, during which local deficits are compensated. Eventually the deficits become too accentuated or the compensatory mechanisms fail [143]. From the results we obtained in this study, I/R injury led to changes in ROS regulation, retinal metabolism, mitochondrial homeostasis and function, retinal vascular function and metal homeostasis, with over half of the altered pathways in the I/R group being self-protective mechanisms. H2S provided additional support where self-protective mechanisms fell short and demonstrated DNA repair properties, eventually providing neurons a better outcome against I/R injury.
Admittedly there are limitations in this study. Firstly, individual retinal samples were deliberately pooled into biological replicates to minimize inter-individual variations [144,145]. The exact role H2S plays in neurodegeneration within the retina is largely vague and still awaits to be thoroughly elucidated. Due to the limitation of sample material and the variety of the signaling pathways H2S is involved in, we cannot confirm the differentially expressed proteins by a second technique in the present study design. As the foremost study providing a thorough overview of the retina proteome changes related to neuroprotective properties of H2S in the retina, the main focus was to acquire a comprehensive perspective of the complex interaction between different proteins. Building on these results, different techniques will definitely be used to confirm the differentially expressed proteins and altered signaling pathways in our future studies.
Secondly, the results attained from the ischemia/reperfusion model are not necessarily valid in other glaucomatous models. There are various experimental models of glaucoma in the marketplace; each of them has specific pros and cons. It seems that degeneration caused by chronic elevated IOP mimics the characteristics of glaucoma better than I/R model. Clinical observations have demonstrated retinal vascular abnormalities and impaired blood flow at the optic nerve head which suggest ischemia plays a key role in the pathogenesis of glaucoma [146,147]. A pure ischemic lesion certainly cannot represent the glaucomatous damage; reperfusion injury is also present in glaucoma patients [148]. It is evident that IOP fluctuations are more damaging than a stabled increased IOP, and reduced circulation due to vascular dysregulation is more damaging than reduced circulation due to arteriosclerosis [149].
This study provides, for the first time, an overall insight into the mainstay retinal proteins and pivotal signaling pathways that interact with H2S to maintain retinal homeostasis against I/R injury. In particular, it reveals that exogenous H2S activates the pathways linked to iron regulation, ROS scavenging, the modulation of mitochondrial homeostasis and function, maintenance of retinal vascular function and GABA receptor signaling. H2S may be a promising and effective therapeutic tool for glaucoma. The findings presented here point to directions for further research, for example, exploring the significance of these identified proteins and pathways and investigating related data from other glaucoma models.

4. Materials and Methods

The overview of sampling and proteomics workflow used in this study is presented in Figure 8.

4.1. Animals

Female Sprague–Dawley rats (n = 12; 250–300 g) at the same age were used for glaucoma animal model in this study. The use of animals for research purposes was approved by the Health Investigation Office Rhineland-Palatinate (permission number: 14-1-085; approvals date: 13 October 2014). All experimental procedures were in accordance with the Association of Research in Vision and Ophthalmology (ARVO)—Statement for the Use of Animals in Ophthalmic and Vision Research, and the guidelines of the Institutional Animal Care and Use Committee. Animals were kept under a day- and night-cycle of 12 h at the Translational Animal Research Center (TARC) of the University Medical Center of Johannes-Gutenberg University Mainz.
Minimizing the discomfort and pain for the animals was prioritized in the experimental interventions. A mixture of medetomidine hydrochlorid (Dorbene vet., Pfizer, New York, NY, USA) and ketamine (Inresa Arzneimittel, Freiburg, Germany) was administered intraperitoneally for anesthesia, and oxybuprocain (Novesine, OmniVision, Puchheim, Germany) was applied topically to ocular surfaces. To reduce post operation pain, novaminsulfon (Novalgin, Ratiopharm, Ulm, Germany) was injected subcutaneously after intervention. Health condition and general behavior of the animals were observed daily by TARC staff.

4.2. Intravitreal Injection of GYY4137

Animals were anesthetized as described above, following topical anesthesia, 3 μL of GYY4137, a H2S slow-releasing donor (SIGMA-ALDRICH; Darmstadt, Germany) was injected into the vitreous body with Hamilton syringe (SIGMA-ALDRICH; Darmstadt, Germany) paired with 33-gauge needle. The injection volume was 3 μL to achieve optimal distribution of the compound and minimum disruption to the IOP [150]. The injection needle was retained intravitreally for 15 s to avoid reflux. The intraocular concentration of GYY4137 was approximately 100 nM as average vitreous volume of an adult rat eye is approximately 56 uL [150].

4.3. Ischemia-Reperfusion Injury Model

The retinal ischemia-reperfusion (I/R) injury model is a well-established animal model which imitates the clinical manifestations of retinal vascular occlusion diseases and acute glaucoma. It has also been widely adapted to study retinal neuronal cell damage. Female Sprague-Dawley rats (n = 12; 250–300 g) were anesthetized, with six receiving an intravitreal injection of GYY4137 in the left eye and the other six receiving intravitreal injections of saline, as described as above. The saline injection group served as the corresponding control with retinae from untouched contralateral eyes being assigned as baseline controls. Following the intravitreal injection, the anterior chamber was entered from the superotemporal cornea with a 30-gauge needle (see Figure 8A). The needle was connected to a sterile saline container, which was lifted until IOP was elevated to 55 mmHg for a period of 60 min. IOP was measured by a rebound-Tonolab (iCare, Vantaa, Finland) for rodent. Central cornea, lens and other surrounding tissues were carefully avoided and not injured in the process. The iris turned pale and the retina lost its red reflex during the procedure, thus confirming the ischemic condition of the eye. Animals were kept alive for 24 h after the intervention for sufficient reperfusion injury.

4.4. Preparation of Retinal Explants

Sprague-Dawley rats were sacrificed under CO2 atmosphere. Eyes were explanted immediately post-mortem and retinae were harvested and flat-mounted as previously described [21]. In short, the eye is dissected into the anterior segment and the optic cup. Intact retina was harvested from the optic cup and flat-mounted on the Millipore filters (Millipore; Millicell, Cork, Ireland) with the ganglion cell side up, vitreous body was then carefully removed (Figure 8B).

4.5. Quantification of Retinal Ganglion Cells

One quarter of each retinal explant was carefully separated under microscope for subsequent immunohistochemical staining against the brain-specific homeobox/POU domain protein 3A (Brn3a). Unlike Thy1, which is another RGC-specific antigen, the expression pattern of Brn3a does not change after retinal injury and the levels of Brn3a protein are decreased with time after retinal injury, which is in agreement with the loss of RGC [151]. Therefore, Brn3a immunodetection is a powerful tool to assess RGC survival in rat injury models [152,153]. Retinal tissue (n = 6 quarters/group) was fixed and stained as previously described [154]. Immunofluorescent RGCs were visualized and photographed with a fluorescent microscope (Carl Zeiss, Ltd., Hertfordshire, UK). Images of retinal whole mounts were photographed from 4 different regions of each quadrant of the retina (Figure 1) using a Zeiss fluorescent microscope (Carl Zeiss, Ltd., Hertfordshire, UK). Images were captured at a 20-fold magnification using a fluorescent camera (Carl Zeiss, Ltd., Hertfordshire, UK). Total numbers of Brn3a-positive cells were counted with the assistance of ImageJ (ImageJ Fiji v_1, total = 4 counts/quadrant, and six retinal quadrants per treatment group). The mean number of RGCs per quadrant was calculated from a mean count at each of the 4 different regions.

4.6. Mass Spectrometry Sample Preparation

The remaining retinal explants were rinsed in ice-cold PBS to remove contaminants and weighed immediately thereafter. Retinal protein extraction from each piece of retina was carried out using T-PER tissue protein extraction reagent (Thermo Scientific Inc., Waltham, MA, USA) following an in-house established method, as described by Manicam et al. [155]. Protein concentration of each eluate was measured by standard bicinchoninic acid (BCA) protein assay kit (Pierce, Rockford, IL, USA) as per manufacturer’s instructions. Following protein measurements, retinal protein samples from respective groups were pooled equally into three biological replicates, represented by R1, R2 and R3. From each replicate, 50 μg protein was subjected to polyacrylamide gel electrophoresis (PAGE). Protein lanes were sliced into 25 bands per replicate and destained, reduced, alkylated, dehydrated and subjected to in-gel trypsin digestion at 37 °C overnight. The peptides were then extracted firstly with acetonitrile and then with a mixture of 5% formic acid and acetonitrile 1:2 (v/v), the supernatant was pooled. The extracted peptides were further purified by SOLAμ SPE plates and cartridges (Thermo Scientific Inc., Waltham, MA, USA) following manufacture’s instructions. The eluate was dried in SpeedVac and dissolved in 10 μL of 0.1% trifluoroacetic acid (TFA) for LC-MS/MS analysis.
The continuum MS data was collected by an ESI-LTQ Orbitrap XL-MS system (Thermo Scientific, Bremen, Germany). The tandem MS spectra were searched against UniProt database (Homo sapiens; Rattus; 21.11.2018). A target-decoy-based false discovery rate (FDR) was set to 0.01 for identification of peptide and protein.
(Figure 8C–F. The detailed sample preparation procedure and general parameters of the instrument can be found in Supplementary Data S3 “Mass Spectrometry Sample Preparation” and Supplementary Data S4 “MaxQuant parameters”)

4.7. Bioinformatics, Functional Annotation and Pathways Analyses and Statistics

Data generated from MaxQuant analysis was subjected to further statistical analysis, carried out with Perseus [156]. Briefly, the data were filtered with a minimum of three valid values in at least one group. The missing values were replaced from normal distribution (width, 0.3; down shift, 1.8) in Perseus. All label-free quantification (LFQ) intensities were subject to a log2 transformation. Followed by a Student’s two-sample t-test for the group’s comparison with p < 0.05 to identify the significantly differentially expressed proteins. Unsupervised hierarchical clustering analysis was done with the z-scores of the LFQ intensities following Euclidean distance (linkage = average; preprocess with k-means) and a heat map is generated to demonstrate the result.
Furthermore, the gene names of significantly differentially expressed proteins (p < 0.05) in each group were subject to functional annotation and pathways analyses by Ingenuity Pathway Analysis (v01-04, IPA; Ingenuity QIAGEN, Redwood City, CA, USA) (https://www.qiagenbioinformatics.com/products/ingenuity-pathway-analysis). Using Benjamini–Hochberg multiple testing correction (−log B–H > 1.3), top canonical pathways of the differentially expressed proteins were presented with p-values calculated (Figure 8G,H).
Prism 8 software (GraphPad Software, Inc., San Diego, CA, USA) was used in this study for statistical calculations of RGC quantification and displaying of the figures. The averaged RGC density was calculated per mm2. Data values are expressed as the mean ± SD. Significance of difference between groups was determined by 1-way ANOVA. Results were considered to be statistically significant when p < 0.05 (Figure 8I).

Supplementary Materials

The following are available online at https://0-www-mdpi-com.brum.beds.ac.uk/1424-8247/13/9/213/s1, Supplementary Data S1: Total proteins, Supplementary Data S2: Differentially expressed proteins, Supplementary Data S3: Mass Spectrometry Sample Preparation, Supplementary Data S4: Maxquant parameters.

Author Contributions

Conceptualization, H.L. and V.P.; methodology, H.L., N.P. and V.P.; software, H.L., N.P. and C.M.; validation, H.L. and V.P.; formal analysis, H.L., N.P. and C.M.; investigation, H.L.; resources, V.P.; data curation, H.L. and V.P.; writing—original draft preparation, H.L.; writing—review and editing, C.M., K.M. and V.P.; visualization, H.L.; supervision, V.P.; project administration, V.P.; funding acquisition, V.P. All authors have read and agreed to the published version of the manuscript.

Funding

This research was supported by Deutsche Forschungsgemeinschaft (DFG; Grant PR1569-1-1).

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Flaxman, S.R.; Bourne, R.R.A.; Resnikoff, S.; Ackland, P.; Braithwaite, T.; Cicinelli, M.V.; Das, A.; Jonas, J.B.; Keeffe, J.; Kempen, J.H.; et al. Global causes of blindness and distance vision impairment 1990–2020: A systematic review and meta-analysis. Lancet Glob. Health 2017, 5, e1221–e1234. [Google Scholar] [CrossRef] [Green Version]
  2. Almasieh, M.; Wilson, A.M.; Morquette, B.; Cueva Vargas, J.L.; Di Polo, A. The molecular basis of retinal ganglion cell death in glaucoma. Prog. Retin. Eye Res. 2012, 31, 152–181. [Google Scholar] [CrossRef]
  3. Keating, D.J. Mitochondrial dysfunction, oxidative stress, regulation of exocytosis and their relevance to neurodegenerative diseases. J. Neurochem. 2008, 104, 298–305. [Google Scholar] [CrossRef] [PubMed]
  4. Tabassum, R.; Jeong, N.Y.; Jung, J. Therapeutic importance of hydrogen sulfide in age-associated neurodegenerative diseases. Neural Regen. Res. 2020, 15, 653–662. [Google Scholar] [CrossRef]
  5. Snyder, S.H.; Jaffrey, S.R.; Zakhary, R. Nitric oxide and carbon monoxide: Parallel roles as neural messengers. Brain Res. Brain Res. Rev. 1998, 26, 167–175. [Google Scholar] [CrossRef]
  6. Verma, A.; Hirsch, D.J.; Glatt, C.E.; Ronnett, G.V.; Snyder, S.H. Carbon monoxide: A putative neural messenger. Science 1993, 259, 381–384. [Google Scholar] [CrossRef] [PubMed]
  7. Bucolo, C.; Drago, F. Carbon monoxide and the eye: Implications for glaucoma therapy. Pharmacol. Ther. 2011, 130, 191–201. [Google Scholar] [CrossRef] [PubMed]
  8. Liu, R.; Flammer, J.; Haefliger, I.O. Isoproterenol, forskolin, and cAMP-induced nitric oxide production in pig ciliary processes. Investig. Ophthalmol. Vis. Sci. 1999, 40, 1833–1837. [Google Scholar]
  9. Meyer, P.; Champion, C.; Schlotzer-Schrehardt, U.; Flammer, J.; Haefliger, I.O. Localization of nitric oxide synthase isoforms in porcine ocular tissues. Curr. Eye Res. 1999, 18, 375–380. [Google Scholar] [CrossRef]
  10. Fleischhauer, J.C.; Beny, J.L.; Flammer, J.; Haefliger, I.O. NO/cGMP pathway activation and membrane potential depolarization in pig ciliary epithelium. Investig. Ophthalmol. Vis. Sci. 2000, 41, 1759–1763. [Google Scholar]
  11. Giuffrida, S.; Bucolo, C.; Drago, F. Topical application of a nitric oxide synthase inhibitor reduces intraocular pressure in rabbits with experimental glaucoma. J. Ocul. Pharmacol. Ther. 2003, 19, 527–534. [Google Scholar] [CrossRef] [PubMed]
  12. Neufeld, A.H.; Das, S.; Vora, S.; Gachie, E.; Kawai, S.; Manning, P.T.; Connor, J.R. A prodrug of a selective inhibitor of inducible nitric oxide synthase is neuroprotective in the rat model of glaucoma. J. Glaucoma 2002, 11, 221–225. [Google Scholar] [CrossRef] [PubMed]
  13. Neufeld, A.H.; Sawada, A.; Becker, B. Inhibition of nitric-oxide synthase 2 by aminoguanidine provides neuroprotection of retinal ganglion cells in a rat model of chronic glaucoma. Proc. Natl. Acad. Sci. USA 1999, 96, 9944–9948. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  14. Maher, P.; Hanneken, A. Flavonoids protect retinal ganglion cells from oxidative stress-induced death. Investig. Ophthalmol. Vis. Sci. 2005, 46, 4796–4803. [Google Scholar] [CrossRef]
  15. Patil, K.; Bellner, L.; Cullaro, G.; Gotlinger, K.H.; Dunn, M.W.; Schwartzman, M.L. Heme oxygenase-1 induction attenuates corneal inflammation and accelerates wound healing after epithelial injury. Investig. Ophthalmol. Vis. Sci. 2008, 49, 3379–3386. [Google Scholar] [CrossRef] [PubMed]
  16. Stagni, E.; Privitera, M.G.; Bucolo, C.; Leggio, G.M.; Motterlini, R.; Drago, F. A water-soluble carbon monoxide-releasing molecule (CORM-3) lowers intraocular pressure in rabbits. Br. J. Ophthalmol. 2009, 93, 254–257. [Google Scholar] [CrossRef]
  17. Gadalla, M.M.; Snyder, S.H. Hydrogen sulfide as a gasotransmitter. J. Neurochem. 2010, 113, 14–26. [Google Scholar] [CrossRef] [Green Version]
  18. Kimura, H. Signaling molecules: Hydrogen sulfide and polysulfide. Antioxid. Redox Signal. 2015, 22, 362–376. [Google Scholar] [CrossRef] [Green Version]
  19. Biermann, J.; Lagreze, W.A.; Schallner, N.; Schwer, C.I.; Goebel, U. Inhalative preconditioning with hydrogen sulfide attenuated apoptosis after retinal ischemia/reperfusion injury. Mol. Vis. 2011, 17, 1275–1286. [Google Scholar]
  20. Si, Y.F.; Wang, J.; Guan, J.; Zhou, L.; Sheng, Y.; Zhao, J. Treatment with hydrogen sulfide alleviates streptozotocin-induced diabetic retinopathy in rats. Br. J. Pharmacol. 2013, 169, 619–631. [Google Scholar] [CrossRef] [Green Version]
  21. Liu, H.; Anders, F.; Thanos, S.; Mann, C.; Liu, A.; Grus, F.H.; Pfeiffer, N.; Prokosch-Willing, V. Hydrogen sulfide protects retinal ganglion cells against glaucomatous injury in vitro and in vivo. Investig. Ophthalmol. Vis. Sci. 2017, 58, 5129–5141. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  22. Yang, G.; Wu, L.; Jiang, B.; Yang, W.; Qi, J.; Cao, K.; Meng, Q.; Mustafa, A.K.; Mu, W.; Zhang, S.; et al. H2S as a physiologic vasorelaxant: Hypertension in mice with deletion of cystathionine gamma-lyase. Science 2008, 322, 587–590. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  23. Kaneko, Y.; Kimura, Y.; Kimura, H.; Niki, I. L-Cysteine inhibits insulin release from the pancreatic beta-cell: Possible involvement of metabolic production of hydrogen sulfide, a novel gasotransmitter. Diabetes 2006, 55, 1391–1397. [Google Scholar] [CrossRef] [Green Version]
  24. Zhang, H.; Bhatia, M. Hydrogen sulfide: A novel mediator of leukocyte activation. Immunopharmacol. Immunotoxicol. 2008, 30, 631–645. [Google Scholar] [CrossRef]
  25. Liu, H.; Mercieca, K.; Anders, F.; Prokosch, V. Hydrogen sulfide and beta-synuclein are involved and interlinked in the aging glaucomatous retina. J. Ophthalmol. 2020, 2020, 8642135. [Google Scholar] [CrossRef] [Green Version]
  26. Hosoya, K.; Nakamura, G.; Akanuma, S.; Tomi, M.; Tachikawa, M. Dehydroascorbic acid uptake and intracellular ascorbic acid accumulation in cultured Muller glial cells (TR-MUL). Neurochem. Int. 2008, 52, 1351–1357. [Google Scholar] [CrossRef] [PubMed]
  27. Spoelstra-de Man, A.M.E.; Elbers, P.W.G.; Oudemans-Van Straaten, H.M. Vitamin C: Should we supplement? Curr. Opin. Crit. Care 2018, 24, 248–255. [Google Scholar] [CrossRef] [PubMed]
  28. Garcia-Krauss, A.; Ferrada, L.; Astuya, A.; Salazar, K.; Cisternas, P.; Martinez, F.; Ramirez, E.; Nualart, F. Dehydroascorbic acid promotes cell death in neurons under oxidative stress: A protective role for astrocytes. Mol. Neurobiol. 2016, 53, 5847–5863. [Google Scholar] [CrossRef]
  29. Gozzelino, R. The pathophysiology of heme in the brain. Curr. Alzheimer Res. 2016, 13, 174–184. [Google Scholar] [CrossRef]
  30. Zhang, D.L.; Ghosh, M.C.; Rouault, T.A. The physiological functions of iron regulatory proteins in iron homeostasis—An update. Front. Pharmacol. 2014, 5, 124. [Google Scholar] [CrossRef] [Green Version]
  31. Gutteridge, J.M.; Halliwell, B. Free radicals and antioxidants in the year 2000. A historical look to the future. Ann. N. Y. Acad. Sci. 2000, 899, 136–147. [Google Scholar] [CrossRef] [PubMed]
  32. Gozzelino, R.; Arosio, P. Iron homeostasis in health and disease. Int. J. Mol. Sci. 2016, 17, 130. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  33. Alavi, F.S.; Gheidi, M.; Zahedi, M.; Safari, N.; Ryde, U. A novel mechanism of heme degradation to biliverdin studied by QM/MM and QM calculations. Dalton Trans. 2018, 47, 8283–8291. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  34. Kapitulnik, J.; Maines, M.D. Pleiotropic functions of biliverdin reductase: Cellular signaling and generation of cytoprotective and cytotoxic bilirubin. Trends Pharmacol. Sci. 2009, 30, 129–137. [Google Scholar] [CrossRef] [PubMed]
  35. Stocker, R. Antioxidant activities of bile pigments. Antioxid. Redox Signal. 2004, 6, 841–849. [Google Scholar] [CrossRef]
  36. Barone, E.; Trombino, S.; Cassano, R.; Sgambato, A.; De Paola, B.; Di Stasio, E.; Picci, N.; Preziosi, P.; Mancuso, C. Characterization of the S-denitrosylating activity of bilirubin. J. Cell. Mol. Med. 2009, 13, 2365–2375. [Google Scholar] [CrossRef]
  37. Chen, W.; Maghzal, G.J.; Ayer, A.; Suarna, C.; Dunn, L.L.; Stocker, R. Absence of the biliverdin reductase-a gene is associated with increased endogenous oxidative stress. Free Radic. Biol. Med. 2018, 115, 156–165. [Google Scholar] [CrossRef]
  38. Sharma, N.; Tramutola, A.; Lanzillotta, C.; Arena, A.; Blarzino, C.; Cassano, T.; Butterfield, D.A.; Di Domenico, F.; Perluigi, M.; Barone, E. Loss of biliverdin reductase-A favors Tau hyper-phosphorylation in Alzheimer’s disease. Neurobiol. Dis. 2019, 125, 176–189. [Google Scholar] [CrossRef]
  39. O’Brien, L.; Hosick, P.A.; John, K.; Stec, D.E.; Hinds, T.D., Jr. Biliverdin reductase isozymes in metabolism. Trends Endocrinol. Metab. TEM 2015, 26, 212–220. [Google Scholar] [CrossRef] [Green Version]
  40. Tudor, C.; Lerner-Marmarosh, N.; Engelborghs, Y.; Gibbs, P.E.; Maines, M.D. Biliverdin reductase is a transporter of haem into the nucleus and is essential for regulation of HO-1 gene expression by haematin. Biochem. J. 2008, 413, 405–416. [Google Scholar] [CrossRef] [Green Version]
  41. Durgin, B.G.; Hahn, S.A.; Schmidt, H.M.; Miller, M.P.; Hafeez, N.; Mathar, I.; Freitag, D.; Sandner, P.; Straub, A.C. Loss of smooth muscle CYB5R3 amplifies angiotensin II-induced hypertension by increasing sGC heme oxidation. JCI Insight 2019, 4. [Google Scholar] [CrossRef] [PubMed]
  42. Haunhorst, P.; Hanschmann, E.M.; Brautigam, L.; Stehling, O.; Hoffmann, B.; Muhlenhoff, U.; Lill, R.; Berndt, C.; Lillig, C.H. Crucial function of vertebrate glutaredoxin 3 (PICOT) in iron homeostasis and hemoglobin maturation. Mol. Biol. Cell 2013, 24, 1895–1903. [Google Scholar] [CrossRef] [PubMed]
  43. Aslund, F.; Ehn, B.; Miranda-Vizuete, A.; Pueyo, C.; Holmgren, A. Two additional glutaredoxins exist in Escherichia coli: Glutaredoxin 3 is a hydrogen donor for ribonucleotide reductase in a thioredoxin/glutaredoxin 1 double mutant. Proc. Natl. Acad. Sci. USA 1994, 91, 9813–9817. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  44. Lillig, C.H.; Berndt, C.; Holmgren, A. Glutaredoxin systems. Biochim. Biophys. Acta 2008, 1780, 1304–1317. [Google Scholar] [CrossRef] [PubMed]
  45. Qi, W.; Li, J.; Chain, C.Y.; Pasquevich, G.A.; Pasquevich, A.F.; Cowan, J.A. Glutathione complexed Fe-S centers. J. Am. Chem. Soc. 2012, 134, 10745–10748. [Google Scholar] [CrossRef] [Green Version]
  46. Netz, D.J.; Stith, C.M.; Stumpfig, M.; Kopf, G.; Vogel, D.; Genau, H.M.; Stodola, J.L.; Lill, R.; Burgers, P.M.; Pierik, A.J. Eukaryotic DNA polymerases require an iron-sulfur cluster for the formation of active complexes. Nat. Chem. Biol. 2011, 8, 125–132. [Google Scholar] [CrossRef] [Green Version]
  47. Rudolf, J.; Makrantoni, V.; Ingledew, W.J.; Stark, M.J.; White, M.F. The DNA repair helicases XPD and FancJ have essential iron-sulfur domains. Mol. Cell 2006, 23, 801–808. [Google Scholar] [CrossRef]
  48. Kispal, G.; Sipos, K.; Lange, H.; Fekete, Z.; Bedekovics, T.; Janaky, T.; Bassler, J.; Aguilar Netz, D.J.; Balk, J.; Rotte, C.; et al. Biogenesis of cytosolic ribosomes requires the essential iron-sulphur protein Rli1p and mitochondria. EMBO J. 2005, 24, 589–598. [Google Scholar] [CrossRef] [Green Version]
  49. Maio, N.; Rouault, T.A. Iron-Sulfur cluster biogenesis in mammalian cells: New insights into the molecular mechanisms of cluster delivery. Biochim. Biophys. Acta 2015, 1853, 1493–1512. [Google Scholar] [CrossRef] [Green Version]
  50. Wachnowsky, C.; Fidai, I.; Cowan, J.A. Cytosolic iron-sulfur cluster transfer-a proposed kinetic pathway for reconstitution of glutaredoxin 3. FEBS Lett. 2016, 590, 4531–4540. [Google Scholar] [CrossRef] [Green Version]
  51. Muhlenhoff, U.; Molik, S.; Godoy, J.R.; Uzarska, M.A.; Richter, N.; Seubert, A.; Zhang, Y.; Stubbe, J.; Pierrel, F.; Herrero, E.; et al. Cytosolic monothiol glutaredoxins function in intracellular iron sensing and trafficking via their bound iron-sulfur cluster. Cell Metab. 2010, 12, 373–385. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  52. Iwema, T.; Picciocchi, A.; Traore, D.A.; Ferrer, J.L.; Chauvat, F.; Jacquamet, L. Structural basis for delivery of the intact [Fe2S2] cluster by monothiol glutaredoxin. Biochemistry 2009, 48, 6041–6043. [Google Scholar] [CrossRef] [PubMed]
  53. Sen, S.; Rao, B.; Wachnowsky, C.; Cowan, J.A. Cluster exchange reactivity of [2Fe-2S] cluster-bridged complexes of BOLA3 with monothiol glutaredoxins. Met. Integr. Biometal Sci. 2018, 10, 1282–1290. [Google Scholar] [CrossRef] [PubMed]
  54. Xia, H.; Li, B.; Zhang, Z.; Wang, Q.; Qiao, T.; Li, K. Human glutaredoxin 3 can bind and effectively transfer [4Fe-4S] cluster to apo-iron regulatory protein 1. Biochem. Biophys. Res. Commun. 2015, 465, 620–624. [Google Scholar] [CrossRef]
  55. Li, H.; Mapolelo, D.T.; Dingra, N.N.; Naik, S.G.; Lees, N.S.; Hoffman, B.M.; Riggs-Gelasco, P.J.; Huynh, B.H.; Johnson, M.K.; Outten, C.E. The yeast iron regulatory proteins Grx3/4 and Fra2 form heterodimeric complexes containing a [2Fe-2S] cluster with cysteinyl and histidyl ligation. Biochemistry 2009, 48, 9569–9581. [Google Scholar] [CrossRef] [Green Version]
  56. Zhang, L.Q.; Cui, H.; Yu, Y.B.; Shi, H.Q.; Zhou, Y.; Liu, M.J. MicroRNA-141-3p inhibits retinal neovascularization and retinal ganglion cell apoptosis in glaucoma mice through the inactivation of Docking protein 5-dependent mitogen-activated protein kinase signaling pathway. J. Cell. Physiol. 2019, 234, 8873–8887. [Google Scholar] [CrossRef]
  57. Wu, B.; Teng, H.; Zhang, L.; Li, H.; Li, J.; Wang, L.; Li, H. Interaction of hydrogen sulfide with oxygen sensing under hypoxia. Oxid. Med. Cell. Longev. 2015, 2015, 758678. [Google Scholar] [CrossRef] [Green Version]
  58. Greco, V.; Spalloni, A.; Corasolla Carregari, V.; Pieroni, L.; Persichilli, S.; Mercuri, N.B.; Urbani, A.; Longone, P. Proteomics and toxicity analysis of spinal-cord primary cultures upon hydrogen sulfide treatment. Antioxidants 2018, 7, 87. [Google Scholar] [CrossRef] [Green Version]
  59. Liu, X.; Pan, L.; Zhuo, Y.; Gong, Q.; Rose, P.; Zhu, Y. Hypoxia-Inducible factor-1alpha is involved in the pro-angiogenic effect of hydrogen sulfide under hypoxic stress. Biol. Pharm. Bull. 2010, 33, 1550–1554. [Google Scholar] [CrossRef] [Green Version]
  60. Kai, S.; Tanaka, T.; Daijo, H.; Harada, H.; Kishimoto, S.; Suzuki, K.; Takabuchi, S.; Takenaga, K.; Fukuda, K.; Hirota, K. Hydrogen sulfide inhibits hypoxia- but not anoxia-induced hypoxia-inducible factor 1 activation in a von hippel-lindau- and mitochondria-dependent manner. Antioxid. Redox Signal. 2012, 16, 203–216. [Google Scholar] [CrossRef] [Green Version]
  61. Xu, J.; Li, J.; Yu, Z.; Rao, H.; Wang, S.; Lan, H. HMGB1 promotes HLF-1 proliferation and ECM production through activating HIF1-alpha-regulated aerobic glycolysis. Pulm. Pharmacol. Ther. 2017, 45, 136–141. [Google Scholar] [CrossRef] [PubMed]
  62. Kim, J.W.; Tchernyshyov, I.; Semenza, G.L.; Dang, C.V. HIF-1-mediated expression of pyruvate dehydrogenase kinase: A metabolic switch required for cellular adaptation to hypoxia. Cell Metab. 2006, 3, 177–185. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  63. Rak, M.; Rustin, P. Supernumerary subunits NDUFA3, NDUFA5 and NDUFA12 are required for the formation of the extramembrane arm of human mitochondrial complex I. FEBS Lett. 2014, 588, 1832–1838. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  64. Peralta, S.; Torraco, A.; Wenz, T.; Garcia, S.; Diaz, F.; Moraes, C.T. Partial complex I deficiency due to the CNS conditional ablation of Ndufa5 results in a mild chronic encephalopathy but no increase in oxidative damage. Hum. Mol. Genet. 2014, 23, 1399–1412. [Google Scholar] [CrossRef] [Green Version]
  65. Nie, H.; Yu, X.; He, H.; Zhou, L.; Li, Q.; Song, C.; Wang, D.; Ren, T.; Chen, Z.; Huang, H.; et al. Hepatocyte miR-33a mediates mitochondrial dysfunction and hepatosteatosis by suppressing NDUFA5. J. Cell. Mol. Med. 2018, 22, 6285–6293. [Google Scholar] [CrossRef] [Green Version]
  66. Liu, Y.; Fiskum, G.; Schubert, D. Generation of reactive oxygen species by the mitochondrial electron transport chain. J. Neurochem. 2002, 80, 780–787. [Google Scholar] [CrossRef]
  67. Kudin, A.P.; Bimpong-Buta, N.Y.; Vielhaber, S.; Elger, C.E.; Kunz, W.S. Characterization of superoxide-producing sites in isolated brain mitochondria. J. Biol. Chem. 2004, 279, 4127–4135. [Google Scholar] [CrossRef] [Green Version]
  68. Flones, I.H.; Fernandez-Vizarra, E.; Lykouri, M.; Brakedal, B.; Skeie, G.O.; Miletic, H.; Lilleng, P.K.; Alves, G.; Tysnes, O.B.; Haugarvoll, K.; et al. Neuronal complex I deficiency occurs throughout the Parkinson’s disease brain, but is not associated with neurodegeneration or mitochondrial DNA damage. Acta Neuropathol. 2018, 135, 409–425. [Google Scholar] [CrossRef] [Green Version]
  69. Burwell, L.S.; Brookes, P.S. Mitochondria as a target for the cardioprotective effects of nitric oxide in ischemia-reperfusion injury. Antioxid. Redox Signal. 2008, 10, 579–599. [Google Scholar] [CrossRef]
  70. Bordt, E.A.; Clerc, P.; Roelofs, B.A.; Saladino, A.J.; Tretter, L.; Adam-Vizi, V.; Cherok, E.; Khalil, A.; Yadava, N.; Ge, S.X.; et al. The Putative Drp1 Inhibitor mdivi-1 is a reversible mitochondrial complex I inhibitor that modulates reactive oxygen species. Dev. Cell 2017, 40, 583–594. [Google Scholar] [CrossRef] [Green Version]
  71. Papandreou, I.; Cairns, R.A.; Fontana, L.; Lim, A.L.; Denko, N.C. HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption. Cell Metab. 2006, 3, 187–197. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  72. Gasior, M.; Rogawski, M.A.; Hartman, A.L. Neuroprotective and disease-modifying effects of the ketogenic diet. Behav. Pharmacol. 2006, 17, 431–439. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  73. Van der Auwera, I.; Wera, S.; Van Leuven, F.; Henderson, S.T. A ketogenic diet reduces amyloid beta 40 and 42 in a mouse model of Alzheimer’s disease. Nutr. Metab. 2005, 2, 28. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  74. Patel, N.V.; Gordon, M.N.; Connor, K.E.; Good, R.A.; Engelman, R.W.; Mason, J.; Morgan, D.G.; Morgan, T.E.; Finch, C.E. Caloric restriction attenuates Abeta-deposition in Alzheimer transgenic models. Neurobiol. Aging 2005, 26, 995–1000. [Google Scholar] [CrossRef] [PubMed]
  75. Lim, G.P.; Calon, F.; Morihara, T.; Yang, F.; Teter, B.; Ubeda, O.; Salem, N., Jr.; Frautschy, S.A.; Cole, G.M. A diet enriched with the omega-3 fatty acid docosahexaenoic acid reduces amyloid burden in an aged Alzheimer mouse model. J. Neurosci. Off. J. Soc. Neurosci. 2005, 25, 3032–3040. [Google Scholar] [CrossRef] [Green Version]
  76. Holmer, H.K.; Keyghobadi, M.; Moore, C.; Menashe, R.A.; Meshul, C.K. Dietary restriction affects striatal glutamate in the MPTP-induced mouse model of nigrostriatal degeneration. Synapse 2005, 57, 100–112. [Google Scholar] [CrossRef]
  77. Tieu, K.; Perier, C.; Caspersen, C.; Teismann, P.; Wu, D.C.; Yan, S.D.; Naini, A.; Vila, M.; Jackson-Lewis, V.; Ramasamy, R.; et al. D-Beta-Hydroxybutyrate rescues mitochondrial respiration and mitigates features of Parkinson disease. J. Clin. Investig. 2003, 112, 892–901. [Google Scholar] [CrossRef] [Green Version]
  78. Prins, M.L.; Fujima, L.S.; Hovda, D.A. Age-Dependent reduction of cortical contusion volume by ketones after traumatic brain injury. J. Neurosci. Res. 2005, 82, 413–420. [Google Scholar] [CrossRef]
  79. Cahill, G.F., Jr.; Veech, R.L. Ketoacids? Good medicine? Trans. Am. Clin. Climatol. Assoc. 2003, 114, 149–161; discussion 162–163. [Google Scholar]
  80. Kashiwaya, Y.; Sato, K.; Tsuchiya, N.; Thomas, S.; Fell, D.A.; Veech, R.L.; Passonneau, J.V. Control of glucose utilization in working perfused rat heart. J. Biol. Chem. 1994, 269, 25502–25514. [Google Scholar]
  81. Sato, K.; Kashiwaya, Y.; Keon, C.A.; Tsuchiya, N.; King, M.T.; Radda, G.K.; Chance, B.; Clarke, K.; Veech, R.L. Insulin, ketone bodies, and mitochondrial energy transduction. FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol. 1995, 9, 651–658. [Google Scholar] [CrossRef] [PubMed]
  82. Wolf, S.; Arend, O.; Sponsel, W.E.; Schulte, K.; Cantor, L.B.; Reim, M. Retinal hemodynamics using scanning laser ophthalmoscopy and hemorheology in chronic open-angle glaucoma. Ophthalmology 1993, 100, 1561–1566. [Google Scholar] [CrossRef]
  83. Harju, M.; Vesti, E. Blood flow of the optic nerve head and peripapillary retina in exfoliation syndrome with unilateral glaucoma or ocular hypertension. Graefe’s Arch. Clin. Exp. Ophthalmol. 2001, 239, 271–277. [Google Scholar] [CrossRef] [PubMed]
  84. Yin, Z.Q.; Vaegan; Millar, T.J.; Beaumont, P.; Sarks, S. Widespread choroidal insufficiency in primary open-angle glaucoma. J. Glaucoma 1997, 6, 23–32. [Google Scholar] [CrossRef] [PubMed]
  85. Flammer, J.; Mozaffarieh, M. Autoregulation, a balancing act between supply and demand. Can. J. Ophthalmol. 2008, 43, 317–321. [Google Scholar] [CrossRef]
  86. Galassi, F.; Giambene, B.; Varriale, R. Systemic vascular dysregulation and retrobulbar hemodynamics in normal-tension glaucoma. Investig. Ophthalmol. Vis. Sci. 2011, 52, 4467–4471. [Google Scholar] [CrossRef] [Green Version]
  87. Zhao, W.; Wang, R. H(2)S-induced vasorelaxation and underlying cellular and molecular mechanisms. Am. J. Physiol. Heart Circ. Physiol. 2002, 283, H474–H480. [Google Scholar] [CrossRef]
  88. Siragusa, M.; Fleming, I. The eNOS signalosome and its link to endothelial dysfunction. Pflug. Arch. Eur. J. Physiol. 2016, 468, 1125–1137. [Google Scholar] [CrossRef] [PubMed]
  89. Sessa, W.C. eNOS at a glance. J. Cell Sci. 2004, 117, 2427–2429. [Google Scholar] [CrossRef] [Green Version]
  90. Tasken, K.; Aandahl, E.M. Localized effects of cAMP mediated by distinct routes of protein kinase A. Physiol. Rev. 2004, 84, 137–167. [Google Scholar] [CrossRef] [Green Version]
  91. Aslam, M.; Hartel, F.V.; Arshad, M.; Gunduz, D.; Abdallah, Y.; Sauer, H.; Piper, H.M.; Noll, T. cAMP/PKA antagonizes thrombin-induced inactivation of endothelial myosin light chain phosphatase: Role of CPI-17. Cardiovasc. Res. 2010, 87, 375–384. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  92. Collins, C.; Osborne, L.D.; Guilluy, C.; Chen, Z.; O’Brien, E.T., 3rd; Reader, J.S.; Burridge, K.; Superfine, R.; Tzima, E. Haemodynamic and extracellular matrix cues regulate the mechanical phenotype and stiffness of aortic endothelial cells. Nat. Commun. 2014, 5, 3984. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  93. Goldfinger, L.E.; Tzima, E.; Stockton, R.; Kiosses, W.B.; Kinbara, K.; Tkachenko, E.; Gutierrez, E.; Groisman, A.; Nguyen, P.; Chien, S.; et al. Localized alpha4 integrin phosphorylation directs shear stress-induced endothelial cell alignment. Circ. Res. 2008, 103, 177–185. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  94. Bakre, M.M.; Zhu, Y.; Yin, H.; Burton, D.W.; Terkeltaub, R.; Deftos, L.J.; Varner, J.A. Parathyroid hormone-related peptide is a naturally occurring, protein kinase A-dependent angiogenesis inhibitor. Nat. Med. 2002, 8, 995–1003. [Google Scholar] [CrossRef] [PubMed]
  95. Jin, H.; Garmy-Susini, B.; Avraamides, C.J.; Stoletov, K.; Klemke, R.L.; Varner, J.A. A PKA-Csk-pp60Src signaling pathway regulates the switch between endothelial cell invasion and cell-cell adhesion during vascular sprouting. Blood 2010, 116, 5773–5783. [Google Scholar] [CrossRef] [Green Version]
  96. Plitzko, B.; Havemeyer, A.; Bork, B.; Bittner, F.; Mendel, R.; Clement, B. Defining the role of the NADH-Cytochrome-b5 Reductase 3 in the mitochondrial amidoxime reducing component enzyme system. Drug Metab. Dispos. Biol. Fate Chem. 2016, 44, 1617–1621. [Google Scholar] [CrossRef]
  97. Wood, K.C.; Durgin, B.G.; Schmidt, H.M.; Hahn, S.A.; Baust, J.J.; Bachman, T.; Vitturi, D.A.; Ghosh, S.; Ofori-Acquah, S.F.; Mora, A.L.; et al. Smooth muscle cytochrome b5 reductase 3 deficiency accelerates pulmonary hypertension development in sickle cell mice. Blood Adv. 2019, 3, 4104–4116. [Google Scholar] [CrossRef]
  98. Rahaman, M.M.; Nguyen, A.T.; Miller, M.P.; Hahn, S.A.; Sparacino-Watkins, C.; Jobbagy, S.; Carew, N.T.; Cantu-Medellin, N.; Wood, K.C.; Baty, C.J.; et al. Cytochrome b5 Reductase 3 Modulates Soluble Guanylate Cyclase Redox State and cGMP Signaling. Circ. Res. 2017, 121, 137–148. [Google Scholar] [CrossRef]
  99. Fukuto, J.M.; Carrington, S.J.; Tantillo, D.J.; Harrison, J.G.; Ignarro, L.J.; Freeman, B.A.; Chen, A.; Wink, D.A. Small molecule signaling agents: The integrated chemistry and biochemistry of nitrogen oxides, oxides of carbon, dioxygen, hydrogen sulfide, and their derived species. Chem. Res. Toxicol. 2012, 25, 769–793. [Google Scholar] [CrossRef]
  100. Samaan, S.; Tranchevent, L.C.; Dardenne, E.; Polay Espinoza, M.; Zonta, E.; Germann, S.; Gratadou, L.; Dutertre, M.; Auboeuf, D. The Ddx5 and Ddx17 RNA helicases are cornerstones in the complex regulatory array of steroid hormone-signaling pathways. Nucleic Acids Res. 2014, 42, 2197–2207. [Google Scholar] [CrossRef]
  101. Dewundara, S.S.; Wiggs, J.L.; Sullivan, D.A.; Pasquale, L.R. Is estrogen a therapeutic target for glaucoma? Semin. Ophthalmol. 2016, 31, 140–146. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  102. Patel, P.; Harris, A.; Toris, C.; Tobe, L.; Lang, M.; Belamkar, A.; Ng, A.; Verticchio Vercellin, A.C.; Mathew, S.; Siesky, B. Effects of sex hormones on ocular blood flow and intraocular pressure in primary open-angle glaucoma: A review. J. Glaucoma 2018, 27, 1037–1041. [Google Scholar] [CrossRef] [Green Version]
  103. Wickham, L.A.; Gao, J.; Toda, I.; Rocha, E.M.; Ono, M.; Sullivan, D.A. Identification of androgen, estrogen and progesterone receptor mRNAs in the eye. Acta Ophthalmol. Scand. 2000, 78, 146–153. [Google Scholar] [CrossRef] [PubMed]
  104. Kobayashi, K.; Kobayashi, H.; Ueda, M.; Honda, Y. Estrogen receptor expression in bovine and rat retinas. Investig. Ophthalmol. Vis. Sci. 1998, 39, 2105–2110. [Google Scholar]
  105. Chakrabarti, M.; Haque, A.; Banik, N.L.; Nagarkatti, P.; Nagarkatti, M.; Ray, S.K. Estrogen receptor agonists for attenuation of neuroinflammation and neurodegeneration. Brain Res. Bull. 2014, 109, 22–31. [Google Scholar] [CrossRef] [Green Version]
  106. Jiang, M.; Ma, X.; Zhao, Q.; Li, Y.; Xing, Y.; Deng, Q.; Shen, Y. The neuroprotective effects of novel estrogen receptor GPER1 in mouse retinal ganglion cell degeneration. Exp. Eye Res. 2019, 189, 107826. [Google Scholar] [CrossRef]
  107. Sarzi, E.; Seveno, M.; Angebault, C.; Milea, D.; Ronnback, C.; Quiles, M.; Adrian, M.; Grenier, J.; Caignard, A.; Lacroux, A.; et al. Increased steroidogenesis promotes early-onset and severe vision loss in females with OPA1 dominant optic atrophy. Hum. Mol. Genet. 2016, 25, 2539–2551. [Google Scholar] [CrossRef] [Green Version]
  108. Pisano, A.; Preziuso, C.; Iommarini, L.; Perli, E.; Grazioli, P.; Campese, A.F.; Maresca, A.; Montopoli, M.; Masuelli, L.; Sadun, A.A.; et al. Targeting estrogen receptor beta as preventive therapeutic strategy for Leber’s hereditary optic neuropathy. Hum. Mol. Genet. 2015, 24, 6921–6931. [Google Scholar] [CrossRef] [Green Version]
  109. Chen, X.; Liu, Y.; Zhang, Y.; Kam, W.R.; Pasquale, L.R.; Sullivan, D.A. Impact of aromatase absence on murine intraocular pressure and retinal ganglion cells. Sci. Rep. 2018, 8, 3280. [Google Scholar] [CrossRef]
  110. Feola, A.J.; Fu, J.; Allen, R.; Yang, V.; Campbell, I.C.; Ottensmeyer, A.; Ethier, C.R.; Pardue, M. Menopause exacerbates visual dysfunction in experimental glaucoma. Exp. Eye Res. 2019, 186, 107706. [Google Scholar] [CrossRef]
  111. Shah, A.; Schiffmacher, A.T.; Taneyhill, L.A. Annexin A6 controls neuronal membrane dynamics throughout chick cranial sensory gangliogenesis. Dev. Biol. 2017, 425, 85–99. [Google Scholar] [CrossRef]
  112. Klee, C.B. Ca2+-dependent phospholipid- (and membrane-) binding proteins. Biochemistry 1988, 27, 6645–6653. [Google Scholar] [CrossRef] [PubMed]
  113. Kapustin, A.N.; Shanahan, C.M. Emerging roles for vascular smooth muscle cell exosomes in calcification and coagulation. J. Physiol. 2016, 594, 2905–2914. [Google Scholar] [CrossRef]
  114. Hubner, C.A.; Schroeder, B.C.; Ehmke, H. Regulation of vascular tone and arterial blood pressure: Role of chloride transport in vascular smooth muscle. Pflug. Arch. Eur. J. Physiol. 2015, 467, 605–614. [Google Scholar] [CrossRef] [PubMed]
  115. Ye, S.; Chang, Y.; Kim, C.W.; Kwon, M.J.; Choi, Y.; Ahn, J.; Kim, J.M.; Kim, H.S.; Shin, H.; Ryu, S. Intraocular pressure and coronary artery calcification in asymptomatic men and women. Br. J. Ophthalmol. 2015, 99, 932–936. [Google Scholar] [CrossRef]
  116. Borden, L.A. GABA transporter heterogeneity: Pharmacology and cellular localization. Neurochem. Int. 1996, 29, 335–356. [Google Scholar] [CrossRef]
  117. Crooks, J.; Kolb, H. Localization of GABA, glycine, glutamate and tyrosine hydroxylase in the human retina. J. Comp. Neurol. 1992, 315, 287–302. [Google Scholar] [CrossRef] [PubMed]
  118. Hilton, E.J.; Hosking, S.L.; Betts, T. The effect of antiepileptic drugs on visual performance. Seizure 2004, 13, 113–128. [Google Scholar] [CrossRef] [Green Version]
  119. Sakaew, W.; Tachow, A.; Thoungseabyoun, W.; Khrongyut, S.; Rawangwong, A.; Polsan, Y.; Masahiko, W.; Kondo, H.; Hipkaeo, W. Expression and localization of VIAAT in distal uriniferous tubular epithelium of mouse. Ann. Anat. Anat. Anz. 2019, 222, 21–27. [Google Scholar] [CrossRef]
  120. Kononenko, N.L.; Puchkov, D.; Classen, G.A.; Walter, A.M.; Pechstein, A.; Sawade, L.; Kaempf, N.; Trimbuch, T.; Lorenz, D.; Rosenmund, C.; et al. Clathrin/AP-2 mediate synaptic vesicle reformation from endosome-like vacuoles but are not essential for membrane retrieval at central synapses. Neuron 2014, 82, 981–988. [Google Scholar] [CrossRef] [Green Version]
  121. Kononenko, N.L.; Classen, G.A.; Kuijpers, M.; Puchkov, D.; Maritzen, T.; Tempes, A.; Malik, A.R.; Skalecka, A.; Bera, S.; Jaworski, J.; et al. Retrograde transport of TrkB-containing autophagosomes via the adaptor AP-2 mediates neuronal complexity and prevents neurodegeneration. Nat. Commun. 2017, 8, 14819. [Google Scholar] [CrossRef] [PubMed]
  122. Helbig, I.; Lopez-Hernandez, T.; Shor, O.; Galer, P.; Ganesan, S.; Pendziwiat, M.; Rademacher, A.; Ellis, C.A.; Humpfer, N.; Schwarz, N.; et al. A recurrent missense variant in AP2M1 impairs clathrin-mediated endocytosis and causes developmental and epileptic encephalopathy. Am. J. Hum. Genet. 2019, 104, 1060–1072. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  123. Kittler, J.T.; Chen, G.; Honing, S.; Bogdanov, Y.; McAinsh, K.; Arancibia-Carcamo, I.L.; Jovanovic, J.N.; Pangalos, M.N.; Haucke, V.; Yan, Z.; et al. Phospho-dependent binding of the clathrin AP2 adaptor complex to GABAA receptors regulates the efficacy of inhibitory synaptic transmission. Proc. Natl. Acad. Sci. USA 2005, 102, 14871–14876. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  124. Froemke, R.C. Plasticity of cortical excitatory-inhibitory balance. Annu. Rev. Neurosci. 2015, 38, 195–219. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  125. Smith, K.R.; Muir, J.; Rao, Y.; Browarski, M.; Gruenig, M.C.; Sheehan, D.F.; Haucke, V.; Kittler, J.T. Stabilization of GABA(A) receptors at endocytic zones is mediated by an AP2 binding motif within the GABA(A) receptor beta3 subunit. J. Neurosci. Off. J. Soc. Neurosci. 2012, 32, 2485–2498. [Google Scholar] [CrossRef] [Green Version]
  126. Neal, M.J.; Shah, M.A. Development of tolerance to the effects of vigabatrin (gamma-vinyl-GABA) on GABA release from rat cerebral cortex, spinal cord and retina. Br. J. Pharmacol. 1990, 100, 324–328. [Google Scholar] [CrossRef]
  127. Hosking, S.L.; Hilton, E.J. Neurotoxic effects of GABA-transaminase inhibitors in the treatment of epilepsy: Ocular perfusion and visual performance. Ophthalmic Physiol. Opt. J. Br. Coll. Ophthalmic Opt. 2002, 22, 440–447. [Google Scholar] [CrossRef]
  128. Hilton, E.J.; Hosking, S.L.; Betts, T. Epilepsy patients treated with antiepileptic drug therapy exhibit compromised ocular perfusion characteristics. Epilepsia 2002, 43, 1346–1350. [Google Scholar] [CrossRef] [Green Version]
  129. Hammond, E.J.; Wilder, B.J. Gamma-vinyl GABA. Gen. Pharmacol. 1985, 16, 441–447. [Google Scholar] [CrossRef]
  130. Wild, J.M.; Martinez, C.; Reinshagen, G.; Harding, G.F. Characteristics of a unique visual field defect attributed to vigabatrin. Epilepsia 1999, 40, 1784–1794. [Google Scholar] [CrossRef]
  131. Fujiwara, M.; Muramatsu, I. Gamma-Aminobutyric acid receptor on vascular smooth muscle of dog cerebral arteries. Br. J. Pharmacol. 1975, 55, 561–562. [Google Scholar] [CrossRef] [PubMed]
  132. Edvinsson, L.; Krause, D.N. Pharmacological characterization of GABA receptors mediating vasodilation of verebral arteries in vitro. Brain Res. 1979, 173, 89–97. [Google Scholar] [CrossRef]
  133. Hinds, K.; Monaghan, K.P.; Frolund, B.; McGeown, J.G.; Curtis, T.M. GABAergic control of arteriolar diameter in the rat retina. Investig. Ophthalmol. Vis. Sci. 2013, 54, 6798–6805. [Google Scholar] [CrossRef] [PubMed]
  134. Deng, X.W.; Dubiel, W.; Wei, N.; Hofmann, K.; Mundt, K.; Colicelli, J.; Kato, J.; Naumann, M.; Segal, D.; Seeger, M.; et al. Unified nomenclature for the COP9 signalosome and its subunits: An essential regulator of development. Trends Genet. TIG 2000, 16, 202–203. [Google Scholar] [CrossRef]
  135. Boussiotis, V.A.; Freeman, G.J.; Taylor, P.A.; Berezovskaya, A.; Grass, I.; Blazar, B.R.; Nadler, L.M. p27kip1 functions as an anergy factor inhibiting interleukin 2 transcription and clonal expansion of alloreactive human and mouse helper T lymphocytes. Nat. Med. 2000, 6, 290–297. [Google Scholar] [CrossRef]
  136. Doronkin, S.; Djagaeva, I.; Beckendorf, S.K. The COP9 signalosome promotes degradation of Cyclin E during early Drosophila oogenesis. Dev. Cell 2003, 4, 699–710. [Google Scholar] [CrossRef] [Green Version]
  137. Yan, J.; Walz, K.; Nakamura, H.; Carattini-Rivera, S.; Zhao, Q.; Vogel, H.; Wei, N.; Justice, M.J.; Bradley, A.; Lupski, J.R. COP9 signalosome subunit 3 is essential for maintenance of cell proliferation in the mouse embryonic epiblast. Mol. Cell. Biol. 2003, 23, 6798–6808. [Google Scholar] [CrossRef] [Green Version]
  138. Hetfeld, B.K.; Peth, A.; Sun, X.M.; Henklein, P.; Cohen, G.M.; Dubiel, W. The COP9 signalosome-mediated deneddylation is stimulated by caspases during apoptosis. Apoptosis Int. J. Program. Cell Death 2008, 13, 187–195. [Google Scholar] [CrossRef] [Green Version]
  139. Da Silva Correia, J.; Miranda, Y.; Leonard, N.; Ulevitch, R.J. The subunit CSN6 of the COP9 signalosome is cleaved during apoptosis. J. Biol. Chem. 2007, 282, 12557–12565. [Google Scholar] [CrossRef] [Green Version]
  140. De Laat, W.L.; Jaspers, N.G.; Hoeijmakers, J.H. Molecular mechanism of nucleotide excision repair. Genes Dev. 1999, 13, 768–785. [Google Scholar] [CrossRef] [Green Version]
  141. Scharer, O.D. Nucleotide excision repair in eukaryotes. Cold Spring Harb. Perspect. Biol. 2013, 5, a012609. [Google Scholar] [CrossRef] [PubMed]
  142. Zhang, M.; Du, W.; Acklin, S.M.; Jin, S.; Xia, F. SIRT2 protects peripheral neurons from cisplatin-induced injury by enhancing nucleotide excision repair. J. Clin. Investig. 2020. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  143. Barros, L.F.; San Martin, A.; Ruminot, I.; Sandoval, P.Y.; Fernandez-Moncada, I.; Baeza-Lehnert, F.; Arce-Molina, R.; Contreras-Baeza, Y.; Cortes-Molina, F.; Galaz, A.; et al. Near-critical GLUT1 and Neurodegeneration. J. Neurosci. Res. 2017, 95, 2267–2274. [Google Scholar] [CrossRef] [Green Version]
  144. Perumal, N.; Funke, S.; Pfeiffer, N.; Grus, F.H. Proteomics analysis of human tears from aqueous-deficient and evaporative dry eye patients. Sci. Rep. 2016, 6, 29629. [Google Scholar] [CrossRef]
  145. Perumal, N.; Funke, S.; Pfeiffer, N.; Grus, F.H. Characterization of lacrimal proline-rich protein 4 (PRR4) in human tear proteome. Proteomics 2014, 14, 1698–1709. [Google Scholar] [CrossRef] [PubMed]
  146. Flammer, J.; Orgul, S.; Costa, V.P.; Orzalesi, N.; Krieglstein, G.K.; Serra, L.M.; Renard, J.P.; Stefansson, E. The impact of ocular blood flow in glaucoma. Prog. Retin. Eye Res. 2002, 21, 359–393. [Google Scholar] [CrossRef]
  147. Osborne, N.N.; Melena, J.; Chidlow, G.; Wood, J.P. A hypothesis to explain ganglion cell death caused by vascular insults at the optic nerve head: Possible implication for the treatment of glaucoma. Br. J. Ophthalmol. 2001, 85, 1252–1259. [Google Scholar] [CrossRef] [Green Version]
  148. Golubnitschaja-Labudova, O.; Liu, R.; Decker, C.; Zhu, P.; Haefliger, I.O.; Flammer, J. Altered gene expression in lymphocytes of patients with normal-tension glaucoma. Curr. Eye Res. 2000, 21, 867–876. [Google Scholar] [CrossRef]
  149. Flammer, J. Glaucomatous optic neuropathy: A reperfusion injury. Klin. Mon. Fur Augenheilkd. 2001, 218, 290–291. [Google Scholar] [CrossRef]
  150. Berkowitz, B.A.; Lukaszew, R.A.; Mullins, C.M.; Penn, J.S. Impaired hyaloidal circulation function and uncoordinated ocular growth patterns in experimental retinopathy of prematurity. Investig. Ophthalmol. Vis. Sci. 1998, 39, 391–396. [Google Scholar]
  151. Nadal-Nicolas, F.M.; Jimenez-Lopez, M.; Sobrado-Calvo, P.; Nieto-Lopez, L.; Canovas-Martinez, I.; Salinas-Navarro, M.; Vidal-Sanz, M.; Agudo, M. Brn3a as a marker of retinal ganglion cells: Qualitative and quantitative time course studies in naive and optic nerve-injured retinas. Investig. Ophthalmol. Vis. Sci. 2009, 50, 3860–3868. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  152. Nadal-Nicolas, F.M.; Sobrado-Calvo, P.; Jimenez-Lopez, M.; Vidal-Sanz, M.; Agudo-Barriuso, M. Long-Term effect of optic nerve axotomy on the retinal ganglion cell layer. Investig. Ophthalmol. Vis. Sci. 2015, 56, 6095–6112. [Google Scholar] [CrossRef] [PubMed]
  153. Nadal-Nicolas, F.M.; Salinas-Navarro, M.; Jimenez-Lopez, M.; Sobrado-Calvo, P.; Villegas-Perez, M.P.; Vidal-Sanz, M.; Agudo-Barriuso, M. Displaced retinal ganglion cells in albino and pigmented rats. Front. Neuroanat. 2014, 8, 99. [Google Scholar] [CrossRef] [Green Version]
  154. Anders, F.; Teister, J.; Liu, A.; Funke, S.; Grus, F.H.; Thanos, S.; von Pein, H.D.; Pfeiffer, N.; Prokosch, V. Intravitreal injection of beta-crystallin B2 improves retinal ganglion cell survival in an experimental animal model of glaucoma. PLoS ONE 2017, 12, e0175451. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  155. Manicam, C.; Perumal, N.; Pfeiffer, N.; Grus, F.H.; Gericke, A. First insight into the proteome landscape of the porcine short posterior ciliary arteries: Key signalling pathways maintaining physiologic functions. Sci. Rep. 2016, 6, 38298. [Google Scholar] [CrossRef] [PubMed]
  156. Manicam, C.; Perumal, N.; Wasielica-Poslednik, J.; Ngongkole, Y.C.; Tschabunin, A.; Sievers, M.; Lisch, W.; Pfeiffer, N.; Grus, F.H.; Gericke, A. Proteomics unravels the regulatory mechanisms in human tears following acute renouncement of contact lens use: A comparison between hard and soft lenses. Sci. Rep. 2018, 8, 11526. [Google Scholar] [CrossRef] [Green Version]
Pharmaceuticals 13 00213 g001 550
Figure 1. Pre-treatment with H2S protects RGC against ischemia-reperfusion injury in vivo. (A–C) Representative fluorescence microscopy of Brn3a staining of retinal explants 24 h after inducing ischemia/reperfusion injury in vivo. (D) Compared to the contralateral control (1310.6 ± 236.4 RGC/mm2), ischemia-reperfusion injury resulted in significant RGC loss in experimental eyes (1101.7 ± 116.4 RGC/mm2). Pretreatment with GYY4137 showed a significant reduction of RGC loss in vivo (1295.4 ± 136.1 RGC/mm2). Total number of RGC between control and H2S treated group is not significantly different (*** p < 0.0005, n = 6/group, means ± SD, scale bar = 50 μm).
Figure 1. Pre-treatment with H2S protects RGC against ischemia-reperfusion injury in vivo. (A–C) Representative fluorescence microscopy of Brn3a staining of retinal explants 24 h after inducing ischemia/reperfusion injury in vivo. (D) Compared to the contralateral control (1310.6 ± 236.4 RGC/mm2), ischemia-reperfusion injury resulted in significant RGC loss in experimental eyes (1101.7 ± 116.4 RGC/mm2). Pretreatment with GYY4137 showed a significant reduction of RGC loss in vivo (1295.4 ± 136.1 RGC/mm2). Total number of RGC between control and H2S treated group is not significantly different (*** p < 0.0005, n = 6/group, means ± SD, scale bar = 50 μm).
Pharmaceuticals 13 00213 g001
Pharmaceuticals 13 00213 g002 550
Figure 2. Retinal proteome of Ischemia-reperfusion (I/R) injured and H2S pre-treated retinae. (A) Representative retinal protein profiles of both I/R injured and H2S pre-treated retinae compared to non-operated retinae (designated as CTRL) resolved in PAGE gel stained with colloidal blue. M: marker. (B) Venn diagram depicting overlaps of identified retinal proteins in I/R injured and H2S pre-treated groups compared to the control group. (C) Heat map depicts the hierarchical clustering of the differentially expressed retinal proteins in I/R injured and H2S pre-treated group compared to the control group, H2S pre-treat group demonstrated a more similar protein makeup to the control group (detailed list of proteins can also be found in Supplementary Data S2).
Figure 2. Retinal proteome of Ischemia-reperfusion (I/R) injured and H2S pre-treated retinae. (A) Representative retinal protein profiles of both I/R injured and H2S pre-treated retinae compared to non-operated retinae (designated as CTRL) resolved in PAGE gel stained with colloidal blue. M: marker. (B) Venn diagram depicting overlaps of identified retinal proteins in I/R injured and H2S pre-treated groups compared to the control group. (C) Heat map depicts the hierarchical clustering of the differentially expressed retinal proteins in I/R injured and H2S pre-treated group compared to the control group, H2S pre-treat group demonstrated a more similar protein makeup to the control group (detailed list of proteins can also be found in Supplementary Data S2).
Pharmaceuticals 13 00213 g002
Pharmaceuticals 13 00213 g003a 550Pharmaceuticals 13 00213 g003b 550
Figure 3. Differential expression profiles of retinal proteins in control, I/R and H2S. The relative protein abundance is represented as heat maps of each protein clusters. (A) A cluster of 48 proteins, the abundance of which were significantly altered due to I/R injury (also see Table 1); (B) a cluster of 18 proteins, the abundance of which were significantly altered due to I/R injury and restored by H2S (Table 2); (D) a cluster of 11 proteins, which were significantly differentially expressed in H2S group (Table 3). Charts showing the different expression profiles of (C) some of the significantly (* p < 0.05) dysregulated proteins in I/R group that were restored due to administration of H2S, (E) some of the significantly differentially expressed retinal proteins in H2S group.
Figure 3. Differential expression profiles of retinal proteins in control, I/R and H2S. The relative protein abundance is represented as heat maps of each protein clusters. (A) A cluster of 48 proteins, the abundance of which were significantly altered due to I/R injury (also see Table 1); (B) a cluster of 18 proteins, the abundance of which were significantly altered due to I/R injury and restored by H2S (Table 2); (D) a cluster of 11 proteins, which were significantly differentially expressed in H2S group (Table 3). Charts showing the different expression profiles of (C) some of the significantly (* p < 0.05) dysregulated proteins in I/R group that were restored due to administration of H2S, (E) some of the significantly differentially expressed retinal proteins in H2S group.
Pharmaceuticals 13 00213 g003aPharmaceuticals 13 00213 g003b
Pharmaceuticals 13 00213 g004 550
Figure 4. Protein–protein interaction networks of the differentially expressed retinal proteins due to I/R comparing to CTRL group. The major interaction networks of differentially expressed retinal proteins obtained by IPA analysis (QIAGEN Inc., https://www.qiagenbioinformatics.com/products/ingenuity-pathway-analysis) in I/R group.
Figure 4. Protein–protein interaction networks of the differentially expressed retinal proteins due to I/R comparing to CTRL group. The major interaction networks of differentially expressed retinal proteins obtained by IPA analysis (QIAGEN Inc., https://www.qiagenbioinformatics.com/products/ingenuity-pathway-analysis) in I/R group.
Pharmaceuticals 13 00213 g004
Pharmaceuticals 13 00213 g005 550
Figure 5. Protein–protein interaction networks of the differentially expressed retinal proteins modulated by H2S. (A) 18 proteins restored by H2S comparing to I/R group. (B) 11 differentially expressed retinal proteins modulated by H2S comparing to CTRL group. The major interaction networks of restored retinal proteins obtained by IPA analysis in H2S group.
Figure 5. Protein–protein interaction networks of the differentially expressed retinal proteins modulated by H2S. (A) 18 proteins restored by H2S comparing to I/R group. (B) 11 differentially expressed retinal proteins modulated by H2S comparing to CTRL group. The major interaction networks of restored retinal proteins obtained by IPA analysis in H2S group.
Pharmaceuticals 13 00213 g005
Pharmaceuticals 13 00213 g006 550
Figure 6. Changes in retinal metabolism, mitochondrial homeostasis and function. Administration of H2S actively inhibited pyruvate dehydrogenase (PDH) complex activity by upregulating HIF1α signaling, therefore limited using glucose as energy source, and suppressed oxidative phosphorylation by inhibiting Complex I activity, consequently increased intracellular oxygen tension under ischemia and limited ROS production during reperfusion. Furthermore, H2S promotes the utilization of ketone bodies as an alternative energy source, which is more energy-efficient than glucose, thus permitted continuous adenosine triphosphate (ATP) production. H2S enhanced the ability of retinal neurons to withstand metabolic stress induced by I/R, therefore less neuronal cell loss.
Figure 6. Changes in retinal metabolism, mitochondrial homeostasis and function. Administration of H2S actively inhibited pyruvate dehydrogenase (PDH) complex activity by upregulating HIF1α signaling, therefore limited using glucose as energy source, and suppressed oxidative phosphorylation by inhibiting Complex I activity, consequently increased intracellular oxygen tension under ischemia and limited ROS production during reperfusion. Furthermore, H2S promotes the utilization of ketone bodies as an alternative energy source, which is more energy-efficient than glucose, thus permitted continuous adenosine triphosphate (ATP) production. H2S enhanced the ability of retinal neurons to withstand metabolic stress induced by I/R, therefore less neuronal cell loss.
Pharmaceuticals 13 00213 g006
Pharmaceuticals 13 00213 g007 550
Figure 7. Changes in retinal vascular function. Due to I/R, PKA (protein kinase A) signaling and NADH-cytochrome b5 reductase 3(Cyb5r3) is upregulated as self-protective mechanism to maintain endothelial function and vasodilation, while eNOS signaling is downregulated as an indication of endothelial dysfunction. Administration of H2S activated estrogen receptor signaling to facilitate vascular relaxation. H2S also reduced the abundance of annexin A6, which plays a central role in artery calcification. Combined together, H2S protected the blood flow regulatory mechanisms and enabled a less constricted vascular environment in retina against I/R injury.
Figure 7. Changes in retinal vascular function. Due to I/R, PKA (protein kinase A) signaling and NADH-cytochrome b5 reductase 3(Cyb5r3) is upregulated as self-protective mechanism to maintain endothelial function and vasodilation, while eNOS signaling is downregulated as an indication of endothelial dysfunction. Administration of H2S activated estrogen receptor signaling to facilitate vascular relaxation. H2S also reduced the abundance of annexin A6, which plays a central role in artery calcification. Combined together, H2S protected the blood flow regulatory mechanisms and enabled a less constricted vascular environment in retina against I/R injury.
Pharmaceuticals 13 00213 g007
Pharmaceuticals 13 00213 g008 550
Figure 8. Workflow overview. (A) I/R injury was induced in the left eyes of adult female Sprague-Dawley rats (n = 12), six of which received intravitreal injection of GYY4137, an H2S slow-releasing precursor, shortly before intervention. (B) Animals were executed 24 h after intervention, retinae were harvested immediately postmortem. (C–E) Retinae from contralateral eyes were designated as controls. Retinal samples were immediately weighed and lysed by T-PER tissue protein extraction reagent and Bullet Blender Storm. Six retinal protein samples from respective groups were pooled equally into three biological replicates after protein measurements, represented by RI, R2 and R3 (N = 3 replicates per group), and subsequently subjected to PAGE. The protein bands were sliced and digested by trypsin prior to proteomic analysis by LC-ESI-MS/MS. (F–H) The emerging datasets were subjected to robust bioinformatics analyses and functional annotations to identify the differential protein expressions and protein interaction networks. (I) To confirm the result of I/R injury and protective effect of H2S in retina, one quarter of each retinal sample (n = 6 per group) were subjected to immunohistochemistry staining against Brn3a for RGC quantification. The averaged RGC density was calculated per mm2. Significance of difference between groups was determined by 1-way ANOVA.
Figure 8. Workflow overview. (A) I/R injury was induced in the left eyes of adult female Sprague-Dawley rats (n = 12), six of which received intravitreal injection of GYY4137, an H2S slow-releasing precursor, shortly before intervention. (B) Animals were executed 24 h after intervention, retinae were harvested immediately postmortem. (C–E) Retinae from contralateral eyes were designated as controls. Retinal samples were immediately weighed and lysed by T-PER tissue protein extraction reagent and Bullet Blender Storm. Six retinal protein samples from respective groups were pooled equally into three biological replicates after protein measurements, represented by RI, R2 and R3 (N = 3 replicates per group), and subsequently subjected to PAGE. The protein bands were sliced and digested by trypsin prior to proteomic analysis by LC-ESI-MS/MS. (F–H) The emerging datasets were subjected to robust bioinformatics analyses and functional annotations to identify the differential protein expressions and protein interaction networks. (I) To confirm the result of I/R injury and protective effect of H2S in retina, one quarter of each retinal sample (n = 6 per group) were subjected to immunohistochemistry staining against Brn3a for RGC quantification. The averaged RGC density was calculated per mm2. Significance of difference between groups was determined by 1-way ANOVA.
Pharmaceuticals 13 00213 g008
Table
Table 1. List of the 48 significantly differentially expressed retinal proteins identified in I/R group.
Table 1. List of the 48 significantly differentially expressed retinal proteins identified in I/R group.
Protein IDsGene Namesp-ValueAbundance
Q15029EFTUD20.0006042low
Q62940Nedd40.00061229low
Q08163Cap10.00086462low
Q7Z5P9MUC190.00091244low
Q9H598SLC32A10.00091751high
Q15181PPA10.0016681high
Q3ZCM7TUBB80.0031885low
Q96CW1AP2M10.00352499high
O75352MPDU10.00377415high
P97519Hmgcl0.00470492low
P34931HSPA1L0.00595437low
P20070Cyb5r30.00814946high
P36871PGM10.00912329high
B0BNE5Esd0.0096494high
Q9UNM6PSMD130.0112771high
Q5XIK2Tmx20.0124046high
P46844BLVRA0.0135271high
Q63524Tmed20.0150562high
Q63598Pls30.0158343low
Q62927Cnga10.0175332low
Q8IX01SUGP20.019042low
P97612Faah0.0195873low
P61203Cops20.0208293high
Q497B0Nit20.0211131high
P39069Ak10.0216897high
P11506Atp2b20.0227347low
Q7TP47Syncrip0.0239965low
Q8NCB2CAMKV0.0247766low
P14854COX6B10.0270203low
P11167Slc2a10.0276784low
P45479Ppt10.0279009high
Q9QZA2Pdcd6ip0.0299058low
P41498Acp10.032686high
P10155TROVE20.0333496high
Q64428Hadha0.0337918low
P83916CBX10.0342579high
Q64560Tpp20.0352463high
P26453Bsg0.0366156high
Q641X8Eif3e0.0387402high
Q6AYR6Hdhd20.0399141high
P08413Camk2b0.0416695high
O08838Amph0.0425382low
Q86V81ALYREF0.0427918high
P63211GNGT10.043069low
P84090ERH0.0437723low
P41542Uso10.0456321low
Q3ZAQ7VMA210.0494713low
P85973Pnp0.0496038high
Table
Table 2. List of 18 retinal proteins which were restored in H2S treated group. Proteins were classified into different categories by PANTHER classification system.
Table 2. List of 18 retinal proteins which were restored in H2S treated group. Proteins were classified into different categories by PANTHER classification system.
Protein ClassGene Namep-ValueAbundance
Cytoskeletal ProteinTUBB80.0031885low
Membrane Traffic ProteinAP2M10.00352499high
Tmed20.0150562high
Metabolite Interconversion EnzymeHmgcl0.00470492low
Nit20.0211131high
Hadha0.0337918low
Nucleic Acid Binding ProteinSUGP20.019042low
Syncrip0.0239965low
Protein Modifying EnzymePSMD130.0112771high
CAMKV0.0247766low
Tpp20.0352463high
Translational ProteinEFTUD20.0006042low
Eif3e0.0387402high
Other ProteinSLC32A10.00091751high
MPDU10.00377415high
Cyb5r30.00814946high
Tmx20.0124046high
Slc2a10.0276784low
Table
Table 3. List of 11 retinal proteins which significantly differentially expressed in H2S treated group comparing to the CTRL group. Proteins were classified into different categories by PANTHER classification system.
Table 3. List of 11 retinal proteins which significantly differentially expressed in H2S treated group comparing to the CTRL group. Proteins were classified into different categories by PANTHER classification system.
Protein ClassGene Namep-ValueAbundance
Calcium-binding ProteinAnxa60.0245515low
Cytoskeletal ProteinDynlrb10.0227117high
Metabolite Interconversion EnzymeGlrx30.0010183high
Ndufa50.0473985low
Nucleic Acid Binding ProteinSNRPG0.0125193low
Translational ProteinRps280.0406697low
COPS60.0463107high
Other ProteinsDDX50.0242271high
KRT10.0326712low
NUP2050.0335003high
CXorf220.0419458low
Table
Table 4. List of most significantly modulated canonical pathways due to I/R.
Table 4. List of most significantly modulated canonical pathways due to I/R.
Canonical Pathways−log(p-Value)ChangesMolecules
Mitochondrial Homeostasis and FunctionKetogenesis3.62DownregulatedHADHA, HMGCL
Protein Ubiquitination Pathway1.7UpregulatedHSPA1L, PSMD13, USO1
Leucine Degradation I1.72DownregulatedHMGCL
Ketolysis1.68DownregulatedHADHA
Neuronal Calcium DysregulationCalcium Transport I1.68UpregulatedATP2B2
Cytotoxicity RegulationFormaldehyde Oxidation II (Glutathione-dependent)2.37DownregulatedESD
Anandamide Degradation2.2UpregulatedFAAH
Purine Ribonucleosides Degradation to Ribose-1-phosphate1.83DownregulatedPNP
Reactive Oxygen Species (ROS) ScavengingHeme Degradation2.07UpregulatedBLVRA
Vitamin-C Transport1.31DownregulatedSLC2A1
Neural TransductionPhototransduction Pathway2.25DownregulatedCNGA1, GNGT1
GABA Receptor Signaling1.76UpregulatedAP2M1, SLC32A1
Vascular FunctioneNOS Signaling1.35DownregulatedCNGA1, HSPA1L
Protein Kinase A Signaling1.29UpregulatedACP1, CAMK2B, CNGA1
I/R vs. CTRL.
Table
Table 5. Clustered overview of H2S regulated canonical pathways. (A) The canonical pathways restored by H2S. (B) The canonical pathways regulated by H2S comparing to CTRL.
Table 5. Clustered overview of H2S regulated canonical pathways. (A) The canonical pathways restored by H2S. (B) The canonical pathways regulated by H2S comparing to CTRL.
Canonical Pathways−log(p-Value)ChangesMolecules
Mitochondrial Homeostasis and FunctionKetogenesis3.78UpregulatedHADHA, HMGCL
Leucine Degradation I1.8UpregulatedHMGCL
Ketolysis1.76UpregulatedHADHA
Neural TransductionGABA Receptor Signaling1.91DownregulatedAP2M1, SLC32A1
ROS RegulationVitamin-C Transport1.38UpregulatedSLC2A1
HIF1α Signaling0.742UpregulatedSLC2A1
Canonical Pathways−log(p-Value)ChangesMolecules
NER pathway1.18UpregulatedCOPS6
Oxidative Phosphorylation1.16DownregulatedNDUFA5
Estrogen Receptor Signaling1.04UpregulatedDDX5
Corticotropin Releasing Hormone Signaling1.02-KRT1
Phagosome Maturation0.708-DYNLRB1
(A) H2S vs. I/R. (B) H2S vs. CTRL.

Share and Cite

MDPI and ACS Style

Liu, H.; Perumal, N.; Manicam, C.; Mercieca, K.; Prokosch, V. Proteomics Reveals the Potential Protective Mechanism of Hydrogen Sulfide on Retinal Ganglion Cells in an Ischemia/Reperfusion Injury Animal Model. Pharmaceuticals 2020, 13, 213. https://0-doi-org.brum.beds.ac.uk/10.3390/ph13090213

AMA Style

Liu H, Perumal N, Manicam C, Mercieca K, Prokosch V. Proteomics Reveals the Potential Protective Mechanism of Hydrogen Sulfide on Retinal Ganglion Cells in an Ischemia/Reperfusion Injury Animal Model. Pharmaceuticals. 2020; 13(9):213. https://0-doi-org.brum.beds.ac.uk/10.3390/ph13090213

Chicago/Turabian Style

Liu, Hanhan, Natarajan Perumal, Caroline Manicam, Karl Mercieca, and Verena Prokosch. 2020. "Proteomics Reveals the Potential Protective Mechanism of Hydrogen Sulfide on Retinal Ganglion Cells in an Ischemia/Reperfusion Injury Animal Model" Pharmaceuticals 13, no. 9: 213. https://0-doi-org.brum.beds.ac.uk/10.3390/ph13090213

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop